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From Chromosomes to Base Pairs
Classical Cytogenetics – From Coloured Bod-
ies to Barcodes
The first illustrations of human chro-mosomes were published in 1882 by
Walther Flemming and in 1888 the term ‘chro-
mosome‘ (Greek for ‘stained body‘) was coined
by Heinrich von Waldeyer [1]. In the beginning
of the 20th century, Theodor Boveri and Wal-
ter Sutton independently proposed that chro-
mosomes carry the hereditary factors, or genes,
and Walter Sutton, who combined cytology and
genetics, was the first to refer to his work as ‘cy-
togenetics‘. In 1923, Thomas Painter reported
the observation of 24 chromosomes in testicu-
lar cells and supposed human somatic cells con-
tained 48 chromosomes [2]. This figure of 48
became generally accepted in the years there-
after and in the end was taken as a given fact
by most cytogeneticists for over three decades.
The correct number was only established in 1956
by Tjio and Levan (Figure 1.1) (3 years after the
publication of the DNA double Helix by Watson
and Crick) with this hesitant statement [3]:
‘Before a renewed, careful control has
been made of the chromosome num-
ber in spermatogonial mitoses of man
we do not wish to generalize our
present findings into a statement that
the chromosome number of man is 2n
= 46, but it is hard to avoid the con-
clusion that this would be the most
natural explanation of our observa-
tions.‘
Figure 1.1 – (left) The
metaphase spread from the
original publication from
Tjio and Levan, establishing
the human chromosome
number as 46 [3]. (bottom)
A normal G-banded female
karyotype.
This discovery was the result of a beautiful ex-
ample of serendipity: prior to slide preparation,
accidental use of a hypotonic rather than an iso-
tonic solution was used to cell suspensions, caus-
ing the cells to swell through osmosis [4]. This
new technique for chromosome spreading made
it possible to unambiguously count the number
of chromosomes, and order them in 7 groups,
based on their length and centromeric position
and heralded the birth of a new discipline: me-
dical cytogenetics.
Soon, the first association between disease and
chromosomes was made when Je´roˆme Lejeune
observed that patients with Down syndrome had
an extra chromosome 21 (trisomy 21) [5]. The
next year, trisomy 13 was recognized as the
cause for Patau Syndrome [6] and trisomy 18
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for Edwards Syndrome [7]. Shortly after these
observations, two frequent disorders of sex dif-
ferentiation were shown to be caused by ab-
normalities in the number of sex chromosomes.
Turner syndrome is caused by monosomy X [8]
and Klinefelter syndrome is caused by an ex-
tra X chromosome in males (47,XXY karyotype)
[9]. This rudimentary technique of chromo-
some spreading also led to the identification of
the first specific chromosomal aberration associ-
ated with human malignancy. Peter Nowell and
David Hungerford described the Philadelphia
chromosome, a supposed deletion of chromo-
some 22, in patients with chronic myelogenous
leukemia [10]. In the ensuing years, human cy-
togenetics evolved by several technological ad-
vances that combined innovations in molecular
biology, chemistry and instrumentation. Peter
Nowell identified phytohemagglutinin, a kidney
bean extract, as a mitogen for lymphocytes [11].
This important discovery made it possible to use
peripheral blood for chromosome analysis, in-
stead of, more invasive, bone marrow aspirates
or fibroblasts. In 1963, it was again Je´roˆme
Lejeune who noted that patients with the Cri-
du-Chat syndrome, a specific syndrome in which
children suffered from severe mental retardation
and a specific cat-like cry, all lacked the terminal
piece of the short arm of chromosome 5. The
first deletion syndrome was identified [12]. A
second milestone in the development of human
cytogenetics, resulted from the study of plant
chromosomes by Torbjo¨rn Caspersson; a fluores-
cent dye (quinacrine) was used to differentially
stain chromosomes. Following this simple stain-
ing procedure, a chromosome specific banding
pattern (Q-banding) was obtained [13]. This
banding greatly facilitated the recognition of
chromosomes and most importantly the detec-
tion of smaller structural defects. Other banding
methods (e.g. G-, R-, C-, and NOR-banding)
rapidly appeared and extended the methodologi-
cal abilities of cytogenetics [14]. A third wave of
innovation in medical cytogenetics resulted from
the introduction of a culture technique that al-
lowed synchronization of the cell cycle and col-
lection of dividing cells in prometaphase. These
elongated prometaphase chromosomes were of
superior quality, exhibiting a much larger num-
ber of chromosome bands and thus offering a
considerable increase in resolution (Figure 1.1)
[15, 16]. These new developments again lead
to a boost in clinical cytogenetics: the un-
derlying genetic chromosomal aberrations were
identified for DiGeorge syndrome [17, 18] and
Williams-Beuren syndrome [19] and the con-
cept of the microdeletion or contiguous gene
syndrome was born [20]. Apart from elucida-
ting the genetic cause of known syndromes, also
new syndromes were described. Smith et al. re-
ported a 17p11 interstitial deletion in nine un-
related patients with specific clinical character-
istics; a syndrome now referred to as Smith-
Magenis syndrome [21].
Through the analysis of chromosome ban-
ding patterns, thousands of recurrent and non-
recurrent chromosomal abnormalities have been
identified in patients with mental retardation
and congenital disorders [22], leading to a better
understanding of the molecular causes of these
disorders and a better patient management.
Molecular Cytogenetics
Fluorescence In Situ Hybridization
Molecular genetics came of age more than a
decade after the introduction of cytogenetics
in clinical medicine. The tremendous oppor-
tunities for diagnosis of monogenic disorders,
in particular after the discovery of PCR-based
methods and improved sequencing strategies
[23–26], quickly overshadowed cytogenetics as
4 Introduction and Research Objectives 
Figure 1.2 – Principle of FISH: probe DNA is propagated in transfected E. coli, isolated, amplified and
labeled either directly or indirectly with respectively a fluorescent reporter or hapten. Labeled probe DNA
is subsequently hybridized onto patients’ metaphase chromosomes or interphase nuclei. (A) Interphase and
metaphase FISH, with probe for 3q telomere (green) and chromosome 3 centromere (red); (B) multi-color
FISH, with all chromosomes labeled in a different color
a discipline. During the late 80s of the previous
century, cytogenetics was a technique receiving
little attention and enthusiasm from clinical ge-
neticists. This however dramatically changed
after the introduction of fluorescent in situ hy-
bridization (FISH) which bridged the gap be-
tween both disciplines and lead to renewed in-
terest in cytogenetics and in particular in the
‘hybrid‘ specialism: molecular cytogenetics. Al-
though in situ hybridization techniques were al-
ready described in 1969 [27, 28], the break-
through came with the introduction of fluores-
cent labeled probes in 1982 [29, 30]. Molec-
ular cytogenetics is based on the principle of
hybridizing DNA probes to the genome (Figure
1.2). Although initially limited by the availabil-
ity of specific DNA probes, FISH rapidly evolved
as an important technique for the fast and sensi-
tive detection of numerical as well as structural
defects both on metaphase chromosomes as in-
terphase nuclei [31–33]. The technique further
evolved and several applications emerged such
as multiplex-FISH, analyses of subtelomeric re-
gions and comparative genomic hybridization.
Multicolor FISH
By making use of various combinations and
concentrations of fluorescent dyes, every chro-
mosome could be visualized in a different
color. Three different techniques make use
of this principle, spectral karyotyping (SKY)
[34], Multiplex-Fluorescence In Situ Hybridiza-
tion (M-FISH) (Figure 1.2.) [35] and COmbined
Binary RAtio labeling (COBRA) [36]. These
techniques were very helpful in the characteri-
zation of complex chromosomal rearrangements
often seen in malignancies [37], but also in some
patients with complex constitutional rearrange-
ments [38].
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Subtelomeric Aberrations
In the mid 1990s, it was noted that the sub-
telomeric regions of chromosomes are gene-
rich and susceptible for chromosomal aberra-
tions [39]. These aberrations, leading to loss
of several genes at the tip of the chromosomes,
were shown to be an important cause for mental
retardation and congenital abnormalities. Us-
ing FISH with subtelomeric specific probes, all
human telomeres could be investigated. Dele-
tions of these telomeric ends were noted in 3
to 10% of patients with mental retardation and
congenital abnormalities [40–42]. Based on the
clinical presentation of patients with subtelo-
meric abnormalities, a checklist for selection of
patients was developed. Important parameters
seemed to be a familial history of mental re-
tardation and the presence of congenital ab-
normalities (growth abnormalities, dysmorphic
features and/or congenital abnormalities) [43].
These characteristics are often referred to as the
‘chromosomal phenotype‘. The clinical features
of patients with subtelomeric deletions were de-
scribed, and it was noted that some subtelo-
meric deletions didn’t seem to have any pheno-
typical effect at all (reviewed in [44], Balikova
et al. in press). Although several improve-
ments were made to the FISH-based technique
[45–49], the procedure remained very labour in-
tensive and expensive. To obtain faster and
cheaper results, molecular strategies like MLPA
(multiplex ligation-dependant probe amplifica-
tion) and MAPH (multiplex amplifiable probe
hybridization) were developed for the detec-
tion of subtelomeric aberrations [50–53]. Some
groups developed subtelomeric arrays [54, 55],
enabling a rapid investigation of all telomeres
and the direct delineation of the size of telom-
eric aberrations.
Because of the high incidence of subtelomeric
deletions in patients with mental retardation
and/or congenital abnormalities (MR/CA), it
was anticipated that not only subtelomeric dele-
tions, but also submicroscopic interstitial dele-
tions were an imported cause for MR/CA. Un-
fortunately, at that time, no whole genome high
resolution screening tools were available to in-
vestigate this hypothesis.
Comparative Genomic Hybridization
A variant of the FISH technique was developed
by the group of Ollie and Anna Kallioniemi, Dan
Pinkel and Joe Gray, and the group of Peter
Lichter [56,57]. Instead of hybridizing probes to
metaphase spreads from the patient, the DNA
of the patient and a reference genome are differ-
entially labeled with fluorophores and hybridized
onto normal control metaphase spreads. With
dedicated software, a fluorescence ratio is calcu-
lated along the axis of each of the chromosomes
and this ratio is a measurement for the relative
copy number status of each region in the DNA
of the patient compared to the reference DNA.
This technique made it possible to detect chro-
mosomal gains and losses in DNA samples where
no karyotype could be obtained (e.g. some tu-
mor samples).
Microarray Comparative Genomic hybridization
In 1997 a variant of CGH was developed [58,59].
Instead of hybridizing the test and reference
DNA to normal metaphase spreads, a microar-
ray of DNA probes immobilized on a glass slide
is used. The fluorescence ratio of each spot on
the array is again a measurement for the relative
copy number status of the locus of that particu-
lar probe in the test DNA compared to the refer-
ence DNA. Despite its relatively early introduc-
tion, it took several years before this array CGH
methodology became more widely used. This
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was mostly due to the restriction in availabil-
ity of appropriate reporters as well as technical
problems related to various aspects of the pro-
cedure [60, 61]. Array CGH is now more widely
applied due to the availability of large sets of val-
idated clones (eg. BAC sets developed for the
Human Genome Project [62]) and the availabil-
ity of commercial platforms, increasing steadily
in density and resolution (BlueGnome, Spec-
tral Genomics). Apart from BAC clone tiling
path arrays which attain a resolution up to 75
kb [63, 64], short oligonucleotide sequences are
increasingly being used allowing further increase
of resolution (Affymetrix, Agilent, Nimblegen).
For smaller genomes or specific sequences, ar-
rays have been developed which can even de-
tect single base-pair alterations [65, 66]. This
new technique called ‘array-based sequencing‘
makes it possible to resequence whole stretches
of DNA for e 1500/Mb.
Closing the Gap
While cytogenetics has evolved to molecular cy-
togenetics, and array platforms are now avail-
able to screen the entire genome for SNP
changes [67–69] or deletions down to 6 kb, the
gap between cytogenetics and molecular genet-
ics is closing. ‘The goal is to do a genome in
minutes or seconds for a $ 1000,‘ says sequenc-
ing pioneer Craig Venter (Nature September
2002), and several leading scientists believe that
technical innovations will make it possible to
achieve this within the next 10 to 15 years [70].
The costs will be insignificant compared to the
medical costs that are involved in the diagnosis
and treatment of patients with constitutional or
somatic genetic aberrations.
Bioinformatics
Starting with the first gene sequenced by the
group of Walter Fiers [23], sequence data
were exponentially generated worldwide. Con-
sequently, the need for databases to store and
explore all these data emerged. Over the
years, huge amounts of transcriptome, pro-
teome, microRNAome, methylome, . . . data
were generated demanding for powerful bioinfor-
matics tools to easily annotate and explore all
this information (regulatory sequences, repeti-
tive sequences, homology etc.). Some of these
databases as well as software tools are grouped
in the ‘National Center for Biotechnology In-
formation‘ (NCBI), the Ensembl and UCSC
Genome Bioinformatics group.
With the advent of microarrays and mass-
spectrometry, another source of high through-
put data came available, with subsequently the
need for specific algorithms and tools to store,
analyze and interpret these data [71–74].
Bioinformatics encompasses the development
and application of computational tools and ap-
proaches to acquire, store, organize, archive,
analyze, or visualize biological, medical behav-
ioral or health data. Bioinformatics involves the
use of applied mathematics, informatics, statis-
tics, computer science, artificial intelligence,
chemistry and biochemistry to solve biological
problems. Several programming languages were
developed or adjusted to address these new
needs. BioPerl is a collection of Perl modules
that facilitate the development of Perl scripts for
bioinformatics applications and has played an es-
sential role in the Human Genome Project. Perl
(Practical Extraction and Report Language) was
first developed by Larry Wall for data extrac-
tion (1987) and is sometimes called: ‘The Swiss
army knife of programming languages‘. A sec-
ond very popular scripting language in bioinfor-
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matics is R. R is a programming language and
software environment for statistical computing.
Specific tools for bioinformatics are grouped in
the open development software project for the
analysis and comprehension of genomic data:
bioconductor [75]. Whereas Perl was mostly
used for genome annotation etc. most R pack-
ages in bioconductor are microarray related. A
third programming language often used in bioin-
formatics is PHP (PHP Hypertext Preproces-
sor), a scripting language originally designed for
producing dynamic web pages.
Although PHP is not specifically designed for
bioinformatics, it is often used due to its flex-
ible nature and ease of use. Several packages
are available for database management, graph-
ical visualizations, mathematical functions, and
bioinformatics tools, making PHP a widely used
general-purpose scripting language especially
suited for web tools (http://www.php.net).
One of the main reasons the Human Genome
Project finished earlier than foreseen, was the
development of these bioinformatics tools, as
well as an enormous improvement in computa-
tional power in the last decades.
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High Resolution DNA Copy Number Analysis
Introduction
Chromosomal aberrations leading toloss or gain of genetic material are an im-
portant cause of constitutional genetic disor-
ders. In addition, acquired chromosome changes
are a common finding in human malignancies.
Standard tools to detect these chromosomal im-
balances are classical methods such as karyotyp-
ing and fluorescence in situ hybridization as in-
dicated above.
Despite the significant improvements made in
cytogenetic technologies, a number of limita-
tions are inherent to these methods. First
of all, karyotyping requires skilled and expe-
rienced laboratory technicians for the delicate
procedure of slide preparation and chromo-
some analysis. A second important limitation
is the resolution which is limited to 5 to 10
Mb, at best [16]. Consequently, all chromo-
some changes detected upon karyotyping impli-
cate large genomic regions encompassing many
genes, whereas smaller changes are inevitably
overlooked. Moreover, the procedure requires
dividing cells, a major drawback of the tech-
nique. However, a major advantage of karyo-
typing remains the fact that in one single ex-
periment the entire genome can be surveyed
for gains and losses of genetic material and the
possibility to detect balanced chromosomal re-
arrangements. Fluorescence in situ hybridiza-
tion (FISH) analysis is frequently used in the
targeted detection of chromosomal gains and
losses. The resolution of FISH is much higher
compared to karyotyping and aberrations down
to 10 kb can be easily detected [76]. This tech-
nique however implies an a priori knowledge of
the genomic region of interest and only a limited
amount of targets can be investigated at the
same time. For many recurrent microdeletion
syndromes with specific phenotypical character-
istics such as the 22q11.2 deletion syndrome,
Smith-Magenis syndrome and Williams-Beuren
syndrome, FISH has been very helpful in the ge-
netic confirmation of the clinical diagnosis.
Molecular Karyotyping
Comparative genomic hybridization (CGH) al-
lows the genome wide detection of chromoso-
mal gains and losses without the need of mitotic
active cells. Like karyotyping however, resolu-
tion is limited to 5-10 Mb [77]. Recent techni-
cal advances enabled an important improvement
of this technique by hybridizing fluorescently la-
beled test and control genomes to DNA probes
immobilized on a glass substrate rather than to
metaphase spreads (Figure 1.3). Different li-
braries of large insert clones (mainly bacterial
artificial chromosomes, BACs) were constructed
for The Human Genome Project [62]. In initial
experiments these large insert clones or alter-
natively, cDNA clones were used as probes to
spot on glass slides and construct the first mi-
croarrays for the detection of genomic imbal-
ances [58, 59, 78]. These microarrays were ini-
tially used to detect chromosomal amplifications
in cancer [79], but after refinement of the tech-
nology it became feasible to detect single copy
number changes, and microarrays were believed
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Figure 1.3 – Principle of array CGH; test and control DNA is differentially labeled with fluorochromes. The
DNA is denaturated and mixed with Cot-1 DNA to block repetitive sequences. The mixture is subsequently
put on a glass slide with immobilized DNA reporters and hybridized. Fluorescence intensities are measured
with a laser scanner and dedicated software.
to be the ultimate tool in the search for small
chromosomal aberrations in human malignancy
and constitutional disorders [80–84]. In anal-
ogy to conventional karyotyping, the genome
wide detection of copy number changes using
microarrays was coined ‘molecular karyotyping‘
[61].
Construction of Microarrays
For the construction of CGH microarrays, BAC
and PAC clones are propagated in bacteria, puri-
fied and then spotted onto a glass slide. As this
approach is labor intensive - BACs and PACs are
single-copy vectors, yielding only low amounts
of DNA - several strategies have been devel-
oped to amplify small amounts of cultured and
purified DNA. A first technique is degenerate
oligonucleotide-primed polymerase chain reac-
tion (DOP-PCR) [85, 86]. Using partially de-
generated primers, all probe DNA is amplified
with one primer-mix. This technique was fur-
ther refined by Fiegler et al. [84] in order to
preferentially amplify human DNA and not con-
taminating E. coli DNA, using human specific
sequences. A second technique used to this pur-
pose was ligation-mediated PCR [82, 87, 88]. In
this method probe DNA is first cut by one or
two specific restriction endonucleases followed
by attachment of an ‘adaptor‘ to the sticky ends.
Finally, all clones are amplified with one single
universal primer, complementary to the adap-
tor. A last technique uses the bacteriophage
φ29 polymerase for rolling circle amplification.
This polymerase can perform strand displace-
ment, proof-reading and isothermal amplifica-
tion of minute amounts of circular and large
fragments of linear DNA with random hexamer
primers [89–91].
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Resolution
The first mature arrays consisted of a few thou-
sand BAC clones obtaining a resolution of ap-
proximately 1 Mb which is an important step for-
ward compared to standard karyotyping [83,84].
As the resolution of array CGH is only dependent
on the amount of probes (reporters) spotted on
the array and the size of these reporters, further
attempts were made to improve the resolution.
Tiling path arrays for certain regions and single
chromosomes [92] were constructed and subse-
quently whole genome tiling path BAC arrays
were developed [63,64,93]. BAC and PACs have
the disadvantage of being relatively large (100-
200 kb) limiting the resolution to ˜75 kb [92].
Moreover these large insert clones contain var-
ious repeats (ALU repeats, LINEs, SINEs, seg-
mental duplications, . . . ) which may hamper
the analysis if present in high number. Expres-
sion arrays using cDNA clones were already de-
scribed in 1995 [94]. Like BAC/PAC libraries,
cDNA libraries are readily available. Moreover,
cDNA clones do not contain repeats and allow
matching results from DNA copy number ana-
lysis with expression studies on the same arrays,
which has important advantages compared to
BACs [95]. However, as several copy number
sensitive regulatory sequences have been iden-
tified outside of coding regions [96–98], cDNA
arrays will not detect changes implicating these
particular regions. Moreover, the signal-to-noise
ratio tends to be lower for cDNA arrays com-
pared to BAC arrays, an important drawback
which has precluded widespread use of these ar-
rays. The Sanger Institute, trailblazers in ar-
ray CGH, used the smaller cosmids and fosmids
as alternative reporters to BACs enabling a res-
olution down to 35 kb. Although this tech-
nique is well suited for smaller, custom arrays,
whole genome analysis would require the cul-
ture and subsequent amplification of 150 000
genomic clones, which is logistically extremely
demanding. Other groups have started using
PCR-based arrays, achieving very high resolu-
tions with repeat-free and non-redundant se-
quences [99, 100]. Constructing whole genome
PCR-arrays requires the design and validation
of hundreds of thousands of PCR primers, impli-
cating the need for bioinformatics tools and PCR
automation. Moreover, the high cost of primers
makes this technique not feasible for a stan-
dard genetic laboratory. Alternatively, synthe-
sised oligonucleotides have been used [101–105].
The ‘in house‘ production of such arrays is far
from evident and fortunately several companies
such as Affymetrix, Nimblegen and Agilent now
offer oligonucleotide arrays on a commercial ba-
sis. New innovative spotting techniques or even
in situ syntheses of the oligonucleotides make
it possible to obtain up to 385 000 reporters
on one microscope slide and hence a theoretical
whole genome resolution down to 6 kb (Nimble-
gen). The practical resolution using these arrays
remains however between 40-60 kb due to the
need of moving reading windows averaging the
probe ratios. Due to repeats in the genome,
some regions are less well represented by probes
while gene-rich regions are more densely covered
with reporters thus providing a higher resolu-
tion. Such oligo-arrays can also be used for cus-
tom projects in order to interrogate a smaller ge-
nomic region rather than the entire genome. Us-
ing tiling oligonucleotide arrays, it is even possi-
ble to (re)sequence stretches of DNA and hence
achieve a resolution up to 1 bp [65, 66]. Some
oligonucleotide arrays were first developed for
whole genome genotyping experiments with the
use of single nucleotide polymorphism (SNP)
specific oligonucleotides, but later turned out to
be also usable for whole genome copy number
analysis (Affymetrix). The advantage of these
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arrays is that not only copy number alterations
can be investigated, but also uniparental disomy
can be detected. These high resolution whole
genome DNA copy number analyses have not
only provided us a lot of clinical information,
but also have revealed a new kind of genomic
variation.
Human Genomic Variation
Two unrelated individuals share about 99.9% of
their DNA sequences, resulting in a 3 million
basepair difference. As the human genome se-
quence was constructed using mostly DNA from
one single individual, the finalization of the hu-
man genome sequence in itself did not provide
full insight into the extent of this variation. In
order to achieve this particular goal, the Inter-
national HapMap Project, was initiated. This
project aims to describe the common patterns
of genetic variation, providing a key resource for
researchers to find genes affecting health, dis-
ease and responses to drugs and environmental
factors. Most studies of human genetic vari-
ation have focused on single nucleotide poly-
morphisms (SNPs). Genetic variation can range
however from these single nucleotide changes to
chromosomal segments extending up to 10 Mb.
Recent studies have used high resolution DNA
copy number analysis techniques to investigate
these larger genetic variations in the popula-
tion [106]. A total of 1447 copy number variable
regions (CNVRs), covering 360 Mb (12% of the
entire human genome) were identified. These
CNVRs encompass more nucleotides than SNPs
identified thus far, underscoring the importance
of CNV in genetic diversity and evolution.
Non Allelic Homologous Recombination (NAHR)
Genetic variation is generated by only a limited
number of mutational processes. An overview
Figure 1.4 – Mutation processes in the hu-
man genome, NAHR (non allelic homologous re-
combination), SNP (single nucleotide polymor-
phism)(adapted from www.sanger.ac.uk)
of these processes is given in figure 1.4.
Diploid species have a significant evolutionary
advantage through a process that is known
as ‘homologous recombination‘ (HR). Homolo-
gous recombination can result in crossover be-
tween homologous chromosomes or in gene con-
version. Crossing over was first described by
Thomas Morgan, and involves the process by
which two homologous chromosomes, paired up
during meiosis, exchange parts of their DNA.
Crossover occurs when homologous sequences,
break and then reconnect but to the different
end piece. During the process of HR, a Holliday
junction is formed, and subsequently genomic
material is exchanged. If they break at the same
place or locus in the sequence of base pairs, the
result is an exchange of chromosomal material
between both parental chromosomes. The out-
come is the normal crossing over product gene-
rating genetic variation. This process is however
error prone. Due to sequence homology between
repeats, the chromatids may not line up exactly
with its corresponding region, leading to unequal
crossing over. Such errors are believed to be re-
sponsible for the formation of VNTRs (variable
number of tandem repeats) occurring through-
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Figure 1.5 – Principle of NAHR (non allelic homologous recombination)
out the genome [107]. If the repeat regions are
larger in size, they are called Low Copy Repeat
elements, or Segmental Duplications [108–110].
Crossing over occurring between such LCRs may
result in the duplication of genes on one chro-
mosome and the deletion of these on the other,
leading to so called ‘genomic disorders‘. This
process is known as non allelic homologous re-
combination (NAHR) (Figure 1.5) [111–115]
Nonhomologous End-Joining (NHEJ)
Another mechanism involved in genomic re-
arrangements is Nonhomologous End-Joining
(NHEJ). This mechanism is much less precise,
and is held responsible for the various transloca-
tions that are associated with cancers, or with
non-recurrent microdeletions and transloca-
tions [115, 116]. NHEJ is the main pathway for
repairing double-stranded DNA breaks in G0,
G1 or early S phases of the cell cycle. Some of
the enzymes involved in direct joining or NHEJ,
are also used to accomplish V(D)J joining for
the antibody variable regions [116, 117].
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Mental Retardation and Congenital Abnormalities
Introduction
Mental retardation occurs in 2-3% ofthe general population (The Arc 2004,
[118–120]) and is defined by the American Asso-
ciation on Intellectual and Developmental Dis-
abilities (AAIDD) as follows:
‘Mental retardation is a disability
characterized by significant limitations
both in intellectual functioning and in
adaptive behavior as expressed in con-
ceptual, social, and practical adaptive
skills. This disability originates before
age 18.‘ (AAMR, 2002)
Intellectual functioning refers to a general men-
tal capability, and intelligence is mostly de-
fined by standardized individually administered
tests that are adjusted for age, socio-economical
background and result in an intelligence quo-
tient (IQ). Adaptive functioning refers to how
effectively individuals cope with everyday life de-
mands. Consideration should be given to the
suitability of the instruments to the subject’s
ethnic and cultural background, education, mo-
tivation, cooperation and associated handicaps
[121]. Often the term ‘developmental delay‘
or ‘developmental disability‘ is used in stead of
‘mental retardation‘, because the latter one has
a negative connotation. According to the De-
velopmental Disabilities Act (Pub. L. 106-402),
the term developmental disability means a se-
vere, chronic disability that:
1. is attributed to a mental or physical im-
pairment or a combination of those impair-
ments;
2. occurs before the individual reaches the age
of 22;
3. is likely to continue indefinitely
4. results in substantial functional limitations
in three or more of the following areas of
major life activities; (i) self care, (ii) re-
ceptive and expressive language, (iii) learn-
ing, (iv) mobility, (v) self-direction, (vi) ca-
pacity for independent living, and (vii) eco-
nomic self-sufficiency; and
5. reflects the individual’s need for a combi-
nation and sequence of special, interdisci-
plinary, or generic services, individualized
supports, or other forms of assistance that
are a long life or extended duration and are
individually planned and coordinated.
Mental retardation can occur as an isolated
developmental disorder or in combination with
other congenital malformations. These associ-
ated abnormalities of normal human morpho-
genesis may express themselves as subtle dys-
morphic signs not causing any physical hand-
icap or present as severe disabling and life-
threatening malformations such as congenital
heart defects.
Diagnosis
The diagnosis of mental retardation requires the
evaluation of the person’s mental capabilities
(IQ) and adaptive skills. The ability to learn,
think, reason, live independently and interact or
function in society will be ascertained. Intellec-
tual functioning, or IQ, is usually measured by
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standardized IQ tests and is usually divided in a
non-verbal and verbal IQ. To measure adaptive
behavior, professionals look at what a child can
do in comparison to other children of his or her
age. The most important skills are: daily living
skills, such as getting dressed, going to the bath-
room, and feeding one’s self; communication
skills, such as understanding what is said and be-
ing able to answer; and social skills with peers,
family members, adults, and others. Because
standardized IQ tests can not be performed with
young children, children are evaluated by assess-
ing the developmental milestones such as the
time of laughing, grasping, sitting unsupported,
and independent walking [121–124]. The di-
agnosis of mental retardation usually requires
a multidisciplinary approach with involvement
of general pediatricians, pediatric neurologists,
clinical geneticists, psychologists and develop-
mental therapists. Taking a personal and fam-
ily history (pedigree) and performing a care-
ful clinical evaluation are essential in the diag-
nostic process. Neuro-imaging studies as well
as electroencephalogram (EEG) recordings and
metabolic studies may be important additional
investigations. Cytogenetic analysis should be
performed in each child with an unexplained
form of mental retardation [121–124].
Classification
Mental retardation varies in severity, and the
World Health Organization proposed to make
a subdivision based on the intelligence quotient
(IQ). The definition and classification of mental
retardation has changed substantially over the
past years, and the latest, published in the Inter-
national Classification of Diseases 10th revision
(ICD-10) [125], is based on the Wechsler Adult
Intelligence Scale (WAIS) (Table 1.1). A very
similar classification is the one from the Ameri-
Table 1.1 – MR-classification according ICD-10
(World Health Organization, 1994)
Classification IQ-score
Mild MR 50-70
Moderate MR 35-50
Severe MR 20-35
Profound MR 0-20
can Psychiatric Association, published in the Di-
agnostic and Statistical Manual of Mental Disor-
ders, 4th edition (DSM-IV) [126]. The AAIDD
classification system focuses more on the capa-
bilities of the retarded individual than on the
limitations. The categories describe the level of
support required (intermittent support, limited
support, extensive support, and pervasive sup-
port). This classification however mirrors the
ICD-10 and DSM-IV classification. Sometimes
a fifth category is added: borderline mental re-
tardation, with IQ scores ranging between 70
and 80. The majority of patients with men-
tal retardation (up to 85%) have mild MR.
About 10% of the mentally retarded popula-
tion is considered moderately retarded, and only
˜5% is classified as severely or profoundly re-
tarded [119,123]. Congenital malformations and
dysmorphic signs are usually found in the latter
two groups.
Etiology
The etiology and pathogenesis of mental re-
tardation is still incompletely understood. Al-
though there is no cure for mental retardation,
a correct diagnosis with identification of the un-
derlying cause is important for several reasons.
The diagnosis is the cornerstone for accurate
genetic counseling. It also allows better man-
agement and estimation of the prognosis. Early
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recognition of the disorder may make preven-
tive measures possible and additional expensive
testing and investigations unnecessary. It usu-
ally brings sort of relief to the parents and helps
them to understand and accept the disabilities
of their affected child [121]. Mental retarda-
tion may be caused by genetic alterations (mu-
tations), environmental factors or a combination
of both. Unfortunately, in at least one-third of
all patients, no cause can be identified, even
after thorough diagnostic evaluation [119]. Sig-
nificant advances in laboratory testing over the
last two decades have led to an important im-
provement in the diagnostic yield. Genetic ab-
normalities are by far the most commonly re-
cognized cause for MR, and can be detected in
about 1/3 of patients [127]. Trisomy 21 is the
most frequent genetic disorder in this group of
patients [119, 127]. Other (non-genetic) causes
include prenatal infections, perinatal asphyxia
and exposure to teratogenic agents during preg-
nancy [127].
Non-genetic or acquired causes of mental retarda-
tion
In this category three different causes can be
distinguished:
Prenatal causes: Maternal infections such as
rubella, toxoplasmosis, and cytomegalovirus
may be transmitted to the developing fetus,
causing mental retardation and congenital ab-
normalities. High blood pressure (hypertension)
or blood poisoning (toxaemia) in the mother
can lead to a reduced oxygen flow to the fetus,
causing brain damage and subsequently men-
tal retardation. Also drug abuse (e.g. alco-
hol) and medications (e.g. valproate) taken
by the mother can result in mental retarda-
tion [127, 128].
Perinatal causes: Perinatal complications lead-
ing to oxygen deprivation or brain hemorrhage
can have a deleterious effect on the developing
brain with mental retardation and cerebral palsy
as a result. Prematurity is a well recognized risk
factor; premature born babies are at higher risk
for exhibiting developmental delay.
Postnatal causes: Infections or injuries of the
central nervous system may result in mental re-
tardation. Mental retardation can be a late-
occurring sequel of fulminant meningitis and en-
cephalitis. Generalized sepsis also puts the af-
fected infant at risk for developing brain dam-
age and consequently mental retardation. Chil-
dren living in poverty are at higher risk due to
malnutrition, unhealthy living conditions, and
improper and inadequate health care. Toxic
agents such as lead poisoning and pesticide
exposure (organophosphates, carbamates, and
pyrethroids) are well known factors causing
mental retardation. Unfortunately, child abuse
still occurs and may result in mental retardation
if brain damage takes place in the developing
child.
Genetic Causes of Mental Retardation
Genetic abnormalities that give rise to mental
retardation are often divided into three broad
categories: chromosomal aberrations, single-
gene disorders and multifactorial disorders. This
subdivision is somewhat arbitrary since chromo-
somal aberrations usually involve one or more
genes in the deleted/duplicated chromosomal
region and therefore could be considered as ei-
ther monogenic or polygenic in nature. The
phenotypic abnormalities may be due to a gene
dosage imbalance of several genes or to the
pleiotropic effect of one single gene. A good
example is the CHARGE syndrome (Coloboma
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of the eye, central nervous system anomalies,
Heart defects, Atresia of the choanae, Retarda-
tion of growth and development, Genital and/or
urinary defects, Ear anomalies and/or deafness),
a condition initially considered to represent a
chromosomal aberration. Researchers world-
wide were searching for the causal microdele-
tion. However after the identification of a mi-
crodeletion through high resolution DNA copy
number analysis in two CHARGE patients, it
turned out that most CHARGE patients had
a mutation in a single gene (CHD7) located
within the deleted interval [129]. CHARGE syn-
drome represents a typical example of pleiotropy
of a single gene defect.
Numerical chromosomal aberrations Most nu-
merical chromosomal aberrations are embryon-
ically lethal resulting in early fetal loss. Fe-
tuses with autosomal trisomies for chromosome
13, 18 and 21 can however survive until birth
[130]. Neonates with trisomy 13 and 18 typi-
cally die shortly after birth due to severe con-
genital malformations of the internal organs.
Life expectancy of children with trisomy 21
has increased enormously due to a better pa-
tient management. Down syndrome or tri-
somy 21, has an incidence of about 1/800 in
live born children, representing the most fre-
quent genetic cause of mental retardation [131].
Down syndrome is characterized by several ma-
jor and minor anomalies. Most individuals with
Down syndrome have mild to moderate men-
tal retardation. The most distinct and recog-
nizable craniofacial features are the flat face
with upslanting palpebral fissures with epican-
thical folds, the flat nasal bridge, protruding
tongue, small ears and redundant skin folds in
the neck. Affected infants are usually hypo-
tonic after birth. They have short hands with
often a single transversal palmer fold (simian
crease). Congenital heart defects are frequently
present and hence a thorough heart examination
should be performed in every infant diagnosed
with Down syndrome. Children with Down syn-
drome have a higher-than-average risk for acute
lymphocytic leukemia (ALL) and acute myeloge-
nous leukemia (AML) [132,133] and adults with
Down syndrome usually develop neuropatholog-
ical changes typical of Alzheimer’s disease by
the age of 40 years [134] (reviewed in [135]).
Although trisomy 21 was the first recognized
chromosomal disorder, thus far only a few genes
contributing to specific phenotypic features have
been identified [136]. By comparing many indi-
viduals with partial trisomy 21, critical regions
were defined [137,138]. However, the definition
of these regions has been controversial as there
are patients with partial triplications outside this
region who, nevertheless, manifest some fea-
tures of Down syndrome [139, 140].
Based on transgenic mouse studies, APP, a gene
coding for the amyloid precursor protein, has
been suspected to play a major role in the cog-
nitive deficits. Overexpression of another gene,
the Avian Erythroblastosis Virus E26 Oncogene
Homolog 2 (ETS2) has been demonstrated to
play a role in apoptosis [141]. Transgenic mice
overexpressing ets2 developed a smaller thy-
mus and lymphocyte abnormalities, character-
istics often observed in patients with Down syn-
drome [142].
Contiguous Gene Disorders Segmental chromo-
somal changes can lead to gene dosage imbal-
ances causing mental retardation or congenital
abnormalities [115,143]. If indeed several genes
are involved in the chromosomal aberration the
term contiguous gene syndrome as proposed by
Schmickel is often used [20]. For some recur-
rent chromosomal aberrations, (some of) the
genes contributing to major phenotypical de-
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fects have been elucidated (Tabel 1.2). As al-
ready indicated, a functional annotation of the
genome is of utmost importance as it provides
insights into the function of genes in normal de-
velopment. For a number of syndromes, the
link between the associated phenotypic features
or at least one of several major manifestations
of the syndrome is evident. This is the case
for example for the LIS1 gene. Loss of func-
tion mutations in this gene cause lissencephaly
(agyria-pachygyria), which is an important com-
ponent of the Miller Dieker syndrome [144]. An-
other well known example is the retinoblastoma
gene, which upon deletion infers a great risk
for development for the embryonal eye tumor
in such patients [145–147]. For most of the
syndromes listed in Table 1.2 however, certain
aspects of the phenotype still remain to be ex-
plained, i.e. the genes contributing to the mal-
formation, congenital defect or mental retarda-
tion remain to be identified. Mouse models can
be instrumental in this respect although they
have their specific limitation e.g. in regard to
facial dysmorphism or simply due to important
differences in certain aspects of developmental
control between humans and mouse. Moreover,
it can be anticipated that haploinsufficiency of
certain genes may influence expression of genes
located on other chromosomal segments not al-
tered by the chromosomal defect [136]. In-
versely, the phenotypic expression (penetrance)
of a given microdeletion syndrome may be al-
tered through the effect of so-called modifiers,
as illustrated for the VCFS syndrome for which
expression and severity seems to be modulated
by the VEGF gene [148].
New Microdeletion/Microduplication Syndromes
With the implementation of microarrays in clini-
cal cytogenetics, recently several new microdele-
tion/duplication syndromes have been identi-
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Figure 1.6 – Del 22q11.2 region on chromosome 22,
refseq genes are shown in blue, low copy repeats in
red. The 3 Mb typical deleted region which is present
in more than 85% of patients with del 22q11.2 syn-
drome and the 1,5 Mb deleted region are shown in
green. The TBX1 gene is shown in red (adapted
from [152])
fied. The Sanger Institute, the Nijmegen group
and the group of Evan Eichler in Seattle re-
ported a new recurrent microdeletion syndrome
on the long arm of chromosome 17 [149–151].
Notably, these 17q21.31 deletions are located
within a genomic region that is known to harbor
a common 900-kb inversion polymorphism that
suppresses recombination between two ancestral
H1 and H2 haplotypes. The H2 lineage, repre-
senting the 900-kb inversion polymorphism, is
found at a frequency of 20% in Caucasians and
can be distinguished from the H1 lineage by a
characteristic 238-bp deletion in intron nine of
the MAPT gene. These H1 an H2 haplotypes
are flanked by Low Copy Repeat (LCR) elements
and the orientation of these LCRs is likely to
facilitate the generation of this microdeletion
by means of non-allelic homologous recombina-
tion [149, 150]. A very similar mechanism was
already described for the 22q11.2 deletion syn-
drome (Figure 1.6) [152], Smith-Magenis syn-
drome [153,154] and Williams-Beuren syndrome
[155]. These LCRs can mediate both deletion
and duplication events as the expected result
from uneven meiotic crossing over and previ-
ously illustrated by the deletion and duplication
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Table 1.2 – Contiguous gene syndromes, locus and genes(s) involved
Syndrome Locus Gene(s)
Wolf-Hirschhorn syndrome 4pter WHSC1, MSX1
Williams-Beuren syndrome 7q11.23 ELN, LIMK1
8p23.1 deletion syndrome 8p23.1 GATA4
Langer-Giedion 8q24.11–q24.13 EXT1, TRPS1
WAGR 11p13 WT1, PAX6
Prader-Willi/Angelman 15q11-q13 SNRPN, NDN, UBE3A
Rubinstein-Taybi 16p13.3 CREBBP
Smith-Magenis 17p11.2 RAI1
Miller-Dieker 17p13.3 LIS1
NF1-microdeletion syndrome 17p NF1
Alagille 20p12 JAG1
22q11.2 deletion 22q11.2 TBX1
of 17p12 leading to Charcot-Marie-Tooth and
HNPP, respectively [156–158]. Recently, the re-
ciprocal of the 7q11.23 deletion (ie the duplica-
tion) in Williams-Beuren syndrome was noted
in some patients with pronounced speech delay,
mental retardation and short stature [159]. An-
other similar emerging syndrome is the 22q11.2
duplication syndrome [160].
Although it is clear that genomic architec-
tural factors like LCRs play a very important
role in the formation of deletions and duplica-
tions, some new recurrent microdeletion syn-
dromes have been described without LCRs at
or near the breakpoints. A good example is the
newly emerging 1p36 deletion syndrome, with
an estimated frequency of 1/5000 - 1/10 000
[161, 162]. 1p36 deletion breakpoints are scat-
tered across the 1p36 region, and although most
deletions extend up to the telomere, some in-
terstitial deletions have been described as well
[163, 164]. Another example is the recently
delineated 12q14 microdeletion syndrome dis-
cussed in this thesis (paper 4 [165]). Other ge-
nomic architectural factors than LCRs are be-
lieved to play a role in these ‘genomic disor-
ders‘, but the exact nature of these sequences
and mechanisms remain to be elucidated.
Single-Gene Disorders Single-gene or mono-
genic disorders are caused by mutations in one
single gene. Single-gene defects can give rise
to a wide variety of diseases or syndromes.
Since many genes control normal brain devel-
opment and normal neuron function, single-
gene disorders are also an important cause of
mental retardation. Distinction is made be-
tween syndromic and non-syndromic (or non-
specific) forms of mental retardation. Mental
retardation can be categorized as syndromic if
it is associated with other physical anomalies
that can range from subtle dysmorphic signs to
gross malformations of internal organs. The dif-
ference between syndromic and non-syndromic
mental retardation is not always that obvious.
Several disorders have been first described as
non-syndromic conditions and have only later
been recognized as syndromic disorders because
of subtle but distinct clinical features, associ-
ated biochemical abnormalities, or specific MRI
findings (e.g. oligophrenin 1 mutations (pa-
per 3 [166]). Moreover, different mutations
in the same gene may have other phenotyp-
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ical consequences, with one mutation associ-
ated with nonspecific mental retardation, and
another with syndromic MR [167]. The most
common single-gene disorder causing mental re-
tardation is the Fragile X syndrome [168].
X-linked Mental Retardation Mental retardation
has a male/female ratio of ˜1,4/1 [169–171].
The most likely explanation is the mandatory
hemizygosity for the X- chromosome in males.
This high ratio has however also lead certain
authors suggest that the X-chromosome harbors
more genes involved in brain functioning in com-
parison to the autosomes [172, 173]. Linkage
analyses in families with X-linked mental retar-
dation have been proven successful in the identi-
fication of the causal genes. By combining these
data from many different families in a world
wide consortium, regions could be diminished
and identification of the causal genes through
mutation analysis was made possible [174]. Also
structural chromosomal abnormalities have been
very helpful in the identification of genes in-
volved in mental retardation [175–178]. Molec-
ular genetic studies can by carried out to identify
the disrupted or deleted genes (paper 3 [166]).
Since the publication and annotation of the Hu-
man Genome Sequence, candidate MR-genes
could be identified based on structure, homol-
ogy and functional domains. At least 140 dif-
ferent forms of syndromic X-linked mental re-
tardation have been described so far and in 66
of these, the causative genetic defect has been
identified [174]. Likewise, 22 genes that play a
role in non-specific X-linked mental retardation
have been identified [179] (Figure 1.7). It is in-
teresting to note that also non-protein-coding
genes may play a role in X-linked mental retar-
dation. Examination of the Sanger database of
microRNAs reveals that a cluster of microRNAs
maps to the Xp11.2-11.3 region, a region that
Figure 1.7 – XLMR genes that are identified by
studying balanced X-chromosome rearrangements
and deletions (or duplications) are in red and green
boxes, respectively; XLMR genes identified by mu-
tation screening are in blue boxes. Boxes that have
a dotted outline indicate candidate genes, the status
of which is still not confirmed. Genes that are impli-
cated in NS-XLMR are shown on the right. (Taken
from [174])
is implicated in 30% of all families with X-linked
mental retardation [180].
Inborn Errors of Metabolism Metabolic disor-
ders are another possible monogenic cause of
mental retardation. Over 350 inborn errors of
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metabolism have been identified, most of which
lead to mental retardation [181]. They usu-
ally show autosomal recessive inheritance. In
some cases (e.g. phenylketonuria (PKU), galac-
tosemia and congenital hypothyroidism), retar-
dation is preventable with early treatment. All
babies in Belgium are tested for these conditions
shortly after birth through a simple heel prick.
Early treatment can prevent the development of
mental retardation in the affected children.
Multifactorial or Complex Inheritance Multifac-
torial disorders are caused by a combination of
multiple factors like genes and environmental
factors. It is highly likely that complex inher-
itance plays an important role in the etiology of
mental retardation. In the publication ‘The Bi-
ology of Mental Defect‘, Lionel Penrose wrote in
1972: ‘the type of inheritance most commonly
observed in human genetic material is due to the
combined actions of more than one gene. In-
deed the number of genes involved can be very
large‘ [182]. In genetically complex disorders,
variation at specific gene loci leads to an in-
creased risk for developing these disorders. Iden-
tification of genes involved in multi-factorial dis-
orders is very complicated due to the complex in-
heritance patterns and the influences of environ-
mental parameters. Variable penetrance, over-
lapping phenotypes and the multitude of possi-
ble targets are all factors hampering the identifi-
cation of the underlying genes. Recent technical
developments have facilitated genome wide as-
sociation studies. The goal of these studies is to
link a certain genomic variant at a specific chro-
mosomal position to a certain condition. With
the advent of these whole genome wide associ-
ation techniques (Illumina, Affymetrix), geneti-
cists try to identify loci involved in common and
complex diseases like mental retardation [183].
Idiopathic Mental Retardation In up to 50% of
patients with mental retardation, no cause can
be identified [127, 184]. It is believed that ge-
netic aberrations are the major factor in these
patients as well. Probably the underlying mech-
anism in these patients is multifactorial or poly-
genic. However also epigenetic modifications
such as aberrant methylation can be involved
[185]. Mental retardation is often a specific and
probably many hundreds or even thousands of
genes may lead to mental retardation if inacti-
vated.
Cytogenetic and Molecular Cytogenetic Inves-
tigations
Chromosomal aberrations are reported in 4 up
to 34% of individuals with mental retardation
[122, 127, 186], and hence, chromosome analy-
sis is an essential test in patients with idiopathic
mental retardation. When a specific syndrome is
suspected, targeted genetic or cytogenetic ana-
lysis can be performed (eg. FMR1 investiga-
tions in patients suspected to have fragile-X
syndrome, FISH analysis for suspected 22q11.2
deletion syndrome, MECP2 investigations in pa-
tients with suspected Rett syndrome etc).
Chromosomal investigations have been proven
to have the highest diagnostic yield in patients
with mental retardation and (multiple) congeni-
tal abnormalities, hence the term ‘chromosomal
phenotype‘ is often used for such patients. As
discussed earlier, the coincidence of several dis-
orders (mental retardation and congenital ab-
normalities) may point to the involvement of
several genes and hence to a contiguous gene
syndrome. With the advent of high resolution
DNA copy number analysis tools as discussed
in this thesis, the diagnostic yield of molecular
cytogenetic investigations in these patients may
improve even significantly.
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Research Objectives
Objective 1: The identification of submicroscopic genomic imbalances in patients
with unexplained mental retardation and congenital abnormalities
The major aim of this thesis was to identify genomic imbalances in patients with unexplained
mental retardation and congenital abnormalities. To this purpose we have introduced the
innovative array CGH technology which allows detection of DNA copy number changes with
much higher resolution than previous whole genome cytogenetic methods. Several patients with
unexplained mental retardation and congenital abnormalities were investigated with array CGH
for the identification of small DNA copy number changes (paper 1).
Objective 2: The study of the incidence and genomic distribution of submicro-
scopic genomic imbalances in patients with idiopathic MR/CA
To achieve this goal, DNA samples from a large cohort of clinically well selected patients with
unexplained mental retardation and congenital abnormalities were screened for submicroscopic
chromosomal aberrations. The results of this screening, together with review of literature
data, lead to the first comprehensive overview of the incidence and genomic distribution of
chromosomal imbalances in patients with idiopathic mental retardation (paper 2).
Objective 3: Identification and characterization of a new chromosomal microdele-
tion syndrome
The identification and registration of new submicroscopic chromosomal aberrations and the
detailed clinical characterization of affected patients as indicated in objectives 1 and 2, has lead
to the identification of a new recurrent microdeletion syndrome (paper 3). In addition, array
CGH analysis has lead to delineation of a 1.8 Mb critical interval on chromosome band 18q12.3
for the known del(18)(q12.1q21) deletion syndrome (paper 4).
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Objective 4: Identification of genes involved in mental retardation and/or congen-
ital abnormalities
In the fourth part of this thesis, array CGH in combination with standard molecular methods was
used in order to identify genes involved in mental retardation and/or congenital abnormalities.
By using array painting on an apparently balanced t(X;9) translocation in a patient with mental
retardation and overgrowth, we were able to identify OPHN1 as the causal gene for the observed
phenotypical abnormalities (paper 5).
Objective 5: Development of a versatile analysis platform for high resolution DNA
copy number analysis
At the time of implementation of the array CGH technology in our laboratory, only a few tools
for array CGH analysis were available. Since all of these tools had important shortcomings,
we decided to develop a dedicated analysis platform which met all our needs for data storage,
analysis and visualization of high resolution DNA copy number analysis (paper 6).
These research objectives will lead to a better understanding of the causes of mental re-
tardation and human malformation and will contribute to identification of genes involved in
development of the brain and other organs.
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Abstract
Screening of a large series of patients with unexplained mental retardation with a 1 Mb BAC array
resulted in the detection of several cryptic chromosomal imbalances. In this paper we present the
findings of array CGH screening in a 14-year-old boy with the brachytelephalangic type of chondro-
dysplasia punctata, mental retardation and obesity. On several occasions, cytogenetic analysis of this
boy revealed a normal karyotype. Subsequent screening with array CGH resulted in the detection of
a distal 9p trisomy and distal Xp nullisomy caused by an unbalanced X;9 translocation:
46,Y,der(X)t(X;9)(p22.32;p23). The identification of this de novo chromosomal rearrangement not
only made accurate genetic counselling possible but also explained most of the phenotypic abnor-
malities observed in this patient. This study confirms the power of array CGH in the detection of
subtle or submicroscopic chromosomal changes.
© 2005 Elsevier SAS. All rights reserved.
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1. Introduction
Mental retardation occurs in 1–3% of the general population [1]. Determining the cause
and establishing the correct diagnosis is usually challenging but essential for accurate genetic
counselling [23]. Chromosomal aberrations represent an important cause of mental retar-
dation. In these situations, the mental retardation is often associated with facial dysmor-
phism and congenital abnormalities. Technological improvements in cytogenetic analysis
such as the introduction of fluorescent in situ hybridisation (FISH) and the availability of
new molecular methods (marker analysis, Multiplex Ligation-dependent Probe Amplifica-
tion) have lead to the detection of new chromosomal imbalances including microdeletions
and subtelomeric deletions [4,17,21]. Although these molecular approaches increase the
resolution of chromosomal investigation, they do not allow a systematic analysis of the
whole genome.
Comparative genomic hybridisation (CGH) was introduced as an alternative whole
genome screening method to karyotyping [3,11]. Although a high resolution method was
developed, CGH still suffered from a limited resolution due to the use of chromosomes as
reporters for the detection of the imbalances [12]. This limitation was overcome by apply-
ing basically the same technique to arrays of spotted DNA clones (e.g. BAC clones, oligo-
nucleotides or cDNA clones) [5,16,22]. More recently SNP chips, originally introduced for
SNP analysis and haplotype mapping, were also shown to be powerful analytical tools for
detection of DNA copy number alterations [10]. Array CGH or SNP chips now offer a
resolution of ~1 Mb or even higher.
Recent studies have shown that, depending upon the selection criteria, in 10–15% of the
patients new submicroscopic deletions or duplications can be detected by array CGH [20,25].
In order to further explore the spectrum of chromosomal defects occurring in patients with
“idiopathic” mental retardation, we initiated a collaborative effort to investigate a series of
100 patients. Details of this study will be presented elsewhere (Maas et al., in preparation).
Here we report the identification of an unbalanced X-autosome translocation in a boy with
mental retardation, obesity, short stature and brachydactyly.
2. Material and methods
2.1. Cytogenetic analysis and FISH
Analysis of G-banded metaphase chromosomes was performed on short-term lympho-
cyte cultures using standard procedures. FISH was performed as described [24]. Probes
used were: subtelomeric probes for chromosome 9 and X, a cosmid clone (34F5) contain-
ing the SHOX gene, a chromosome X centromere specific probe and painting probe and
selected BAC clones for distal 9p (RP11-48M17, RP11-106A1, RP11-352F21, RP11-
187K14).
2.2. Array CGH analysis
DNA was isolated from total blood using the Puregene Genomic DNA Purification Kit
(Gentra Systems), according to the manufacturer’s instructions. Using random prime label-
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ling, 500 ng of patient and control female DNA was labelled with Cy3 and Cy5 (BioPrime
Array-CGH Genomic Labelling System, Invitrogen). The labelled fragments were sup-
pressed with 150 µg fluorometric QC Cot-1 DNA (Invitrogen) and 400 µg yeast tRNA, and
resuspended in 60 µl hybridisation buffer at 37 °C (50% formamide, 10% dextran sulphate,
0.1% Tween 20, 2× SSC, 10 mM Tris pH 7.4). In house produced 1 Mb resolution BAC
arrays consisting of 3431 clones spotted in triplicate on CodeLink Activated slides (Amer-
sham Biosciences) were prehybridised at 37 °C during 1 h using 100 µg fluorometric QC
Cot-1 DNA (Invitrogen) and 150 µg herring sperm DNA, resuspended in 120 µl hybridisa-
tion buffer. After removal of the prehybridisation mixture, patient and control DNA was
simultaneously hybridised for 48 h at 37 °C. The slides were washed in 1× PBS/0.05%
Tween 20 for 10 min at room temperature, 50% formamide/2× SSC for 30 min at 42 °C and
finally 1× PBS/0.05% Tween 20 for 10 min at room temperature. After centrifuge drying,
the slides were scanned using a GMS 418 Array Scanner (MWG). The scan images were
processed with Imagene software (Biodiscovery) and further analysed with our in house
developed and freely available software tool arrayCGHbase (http://medgen.ugent.be/
arraycghbase/) [14]. Reporters were excluded from analysis if one of the following criteria
were fulfilled: signal to noise ratio < 3; standard deviation of the log2 transformed ratios
between triplicates > 0.2; and only one informative replicate.
3. Case report
The proband was born at term after an uncomplicated pregnancy. Birth weight was 3250 g,
length 48 cm and head circumference 34.5 cm. He is the youngest son of healthy, non-
consanguineous parents. The family history is unremarkable. The perinatal course was
uneventful. At the age of 1 month, cytogenetic analysis was performed because of hypoto-
nia, facial dysmorphism with small, deeply set nose, and short limbs with brachydactyly. A
normal male karyotype was found. Because of persistent hypotonia and growth failure, he
was re-evaluated at the age of 3 months. Echocardiogram, MRI brain, hearing tests and an
ophthalmological evaluation all revealed normal findings. He started walking at 14 months.
Excessive weight gain was observed around the age of 3 years. At the age of 5 years he was
referred to the genetic outpatient clinic because of short stature, obesity and mental retar-
dation. He was following special education school because of moderate mental retardation
(full scale IQ 58). Verbal performance was more impaired than perceptual and motor func-
tion. His language development was delayed and his speech was very difficult to under-
stand due to poor language skills and articulation problems. Physical examination at the
age of 5 years revealed a weight of 22 kg (P90; BMI = 22.2), length of 99.5 cm (–2.5 S.D.)
and head circumference of 52.3 cm (P50–P98). The face was round with flat profile and
high forehead (Fig. 1a–c). Remarkably was the short nose with low nasal bridge and
anteverted nares. Truncal obesity with inverted nipples was present. The genitalia were
male with small scrotum and both testes in the inguinal canals. The hands were short with
brachydactyly and bilateral simian crease. Of note were the short distal phalanges of third
and fourth fingers (Fig. 1d). Cytogenetic analysis was repeated but found to be normal at
the 550 band stage. Prader–Willi syndrome (PWS) was excluded based on DNA-based
methylation testing of the PWS region on chromosome 15q11.2-q13. Analysis of the FMR1
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gene revealed a normal methylation pattern and number of CGG trinucleotide repeats.
Because of the brachydactyly, radiographs of the hands were taken. These films showed
bilaterally short and dysplastic distal phalanges of the third and fourth fingers on both
hands (Fig. 2b). Evaluation of earlier hand radiographs did not reveal punctuate calcifica-
tions but changes reminiscent for the brachytelephalangic type of chondrodysplasia punc-
tata (MIM 302950) (Fig. 2a). Radiographic evaluation of the remaining parts of the skel-
Fig. 1. The proband at the age of 5 years. The boy is short and obese (a). Note the flat facial profile with small,
deeply set nose (b, c). The hands are short with small and broad nails on third and fourth fingers (d).
Fig. 2. Radiographs of the left hand at different ages. (a) Radiograph at the age of 1 year shows short distal
phalanges in fingers II–V. The shape of the third and fourth distal phalanx resembles an inverted triangle. Punctate
calcifications are not seen. (b) At the age of 5 years mainly the distal phalanges of third and fourth finger are short
and dysplastic. The epiphysis seems to be attached to the body of the phalanx that still has an inverted triangle
shape. (c) The distal phalanges of third and fourth finger remain small at the age of 9 years due to premature
closure of the growth plate. There is also mild shortening of the distal phalanx of second finger and middle
phalanx of fifth finger. (d) Similar findings are found on the radiograph taken at the age of 12 years.
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eton did not show other abnormalities or areas with punctuate calcifications. The possibility
of a microdeletion on the short arm of the X-chromosome, encompassing the ARSE gene,
was considered. However, molecular analysis at that time failed to detect any abnormalities
of the ARSE gene. On follow-up the boy developed severe obesity with hyperinsulinism
(Fig. 3). Weight and height at the age of 14 years 4 months were 85.8 kg (P97 = 82 kg;
BMI = 41.4) and 144 cm (–3.2 S.D.), respectively.
4. Results
Array CGH analysis revealed a gain of distal chromosome 9p material. An array CGH-
base representation [14] of the array CGH profile for chromosome 9 is shown in Fig. 4.
Evidence for copy number gain was obtained for a total of nine BAC clones representing a
region encompassing 12.9 Mb with breakpoints located between clones RP11-187K14
(12872920bp) and RP11-490C5 (15298239bp). This corresponds to a duplication for chro-
mosomal segment 9pter → p23.
Array CGH results were validated by FISH for BAC clones located within the regio
showing copy number gain. These hybridisations confirmed an extra copy for each of the
investigated clones. For each of the clones the extra signal was located at the distal end of
the short arm of the X-chromosome as determined by DAPI counter staining. This was
further confirmed using a chromosome X painting probe. FISH with chromosome X and Y
subtelomeric probes demonstrated loss of subtelomeric sequences at Xpter. FISH also con-
firmed deletion of the SHOX gene. BAC reporters for the pseudo-autosomal region were
excluded from the array CGH analysis for technical reasons and thus could not be assessed.
Further array CGH and FISH is ongoing in order to map the distal Xp breakpoint in more
detail.
Karyotyping and FISH analysis of both parents yielded normal results indicating that
the unbalanced X;9 translocation occurred de novo. The karyotype of the proband is there-
fore written as: 46,Y,der(X)t(X;9)(p22.32;p23) de novo.
Fig. 3. The proband at the age of 7.5 years showing severe obesity.
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5. Discussion
The proband is the first reported case of a cryptic unbalanced X-autosome translocation,
ultimately detected with array CGH. This analysis showed that the distal part of the short
arm of chromosome 9 was translocated onto the short arm of the X-chromosome leading to
a partial trisomy of the 9pter → p23 segment and to a nullisomy of the Xp22.3-pter seg-
ment. On several occasions before, the boy was investigated with cytogenetic analysis that
revealed repeatedly a normal male karyotype. The presence of only one X-chromosome in
males may hamper the meticulous analysis of this chromosome in the absence of its coun-
terpart. This may explain why the translocation in our case was missed despite the fact that
the 9p segment was approximately 12 Mb in size. Molecular tests also failed to unravel the
genetic cause of his rather complex phenotype. While the boy had features of the brachytele-
phalangic type of chondrodysplasia punctata, his overall phenotype did not resemble that
Fig. 4. Top panel shows a chromosome 9 representation of the array-CGH result mapping the relative fluores-
cence signal (patient versus sex-mismatched control) of all BAC reporters onto their chromosomal position (for
details see Section 2). Lower panels show the result of FISH on metaphases from the patient using a subtelomeric
9p probe in combination with an X-chromosome painting probe (right) and telomeric probes for the X- and
Y-chromosome (left).
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observed in patients with either mutations or microdeletions involving the ARSE gene on
Xp22.3 [2,6,15,19].
X-autosome translocations occur both in males and females and can be balanced or
unbalanced. The consequences of the presence of an X-autosome translocation can be very
different for males and females. In females with balanced X-autosome translocations, the
normal X-chromosome will be preferentially inactivated whereas in case of an unbalanced
translocation the pattern of inactivation will be the one leading to the least functional imbal-
ance. Male carriers of a balanced X-autosome translocation are mostly normal but have an
impaired spermatogenesis and infertility. In males with unbalanced X;autosome transloca-
tions either in utero lethality or mental retardation with congenital abnormalities can be
observed [7,8].
Our patient clearly shows features of the brachytelephalangic type of chondrodysplasia
punctata. He has a flat face with very small nose, low nasal bridge and anteverted nares. In
addition, he has hypoplasia of some distal phalanges that show at an early age an inverted
triangle shape as is typically observed in this type of chondrodysplasia. Puncta are usually
restricted to the hands and feet, disappear at an early age and may therefore be missed later
on in life. It has been shown that mutations in the ARSE gene can cause the brachytelepha-
langic type of chondrodysplasia punctata [2,6,15,19]. The ARSE gene is located in the Xp
segment deleted in our patient. We therefore conclude that the chondrodysplasia in this boy
is due to the deletion of the distal part of the X-chromosome. The SHOX gene is also
located in this chromosomal fragment and may therefore be a contributory factor to the
growth failure. Both the mental retardation and short stature are most likely the result of a
combined effect of the partial trisomy and partial nullisomy. Mental retardation and short
stature are constant features of the dup (9p) syndrome [18]. Of interest is the paper by
Lewandowski et al. [13] reporting a patient with dup(9)(p24 → p21) who showed mental
retardation but with disproportionally defective language as is observed in our proband.
This may suggest that at least one gene on 9p is important for proper language development
and understandable speech. Obesity has to our knowledge not been reported in patients
with a duplication of the short arm of chromosome 9. However, one family (family MRX43)
with the association of X-linked mental retardation and obesity has been reported and linked
to the region Xp22.31-p21.2, suggesting that at the distal tip of the short arm of the
X-chromosome a gene is located that controls body weight [9].
The present report nicely illustrates the new possibilities offered for sensitive screening
of submicroscopic chromosomal imbalances. We are now witnessing a more widespread
application of this whole genome screening method in the study of unexplained mental
retardation, and ultimately a routine based screening can be expected to be developed. The
screening of larger series of patients will yield substantial new information on the genetic
basis of mental retardation and malformations. This wealth of information will lead to the
further description of the so-called morbid genome, a challenge that will need careful col-
lection of genetic and clinical data. To this purpose a new database called DECIPHER has
been launched (http://www.sanger.ac.uk/PostGenomics/decipher/). In parallel, an inven-
tory needs to be made of chromosomal regions that are polymorphic and tolerate copy
number alterations without phenotypic effect. Finally, these studies may unveil perhaps
new classes of hitherto undetected types of chromosomal changes such as the previously
detected subtelomeric deletions and duplications due to segmental duplications.
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Background: Chromosomal abnormalities are a major cause of mental retardation and multiple congenital
anomalies (MCA/MR). Screening for these chromosomal imbalances has mainly been done by standard
karyotyping. Previous array CGH studies on selected patients with chromosomal phenotypes and normal
karyotypes suggested an incidence of 10–15% of previously unnoticed de novo chromosomal imbalances.
Objective: To report array CGH screening of a series of 140 patients (the largest published so far) with
idiopathic MCA/MR but normal karyotype.
Results: Submicroscopic chromosomal imbalances were detected in 28 of the 140 patients (20%) and
included 18 deletions, seven duplications, and three unbalanced translocations. Seventeen of 24
imbalances were confirmed de novo and 19 were assumed to be causal. Excluding subtelomeric
imbalances, our study identified 11 clinically relevant interstitial submicroscopic imbalances (8%). Taking
this and previously reported studies into consideration, array CGH screening with a resolution of at least
1 Mb has been undertaken on 432 patients with MCA/MR. Most imbalances are non-recurrent and
spread across the genome. In at least 8.8% of these patients (38 of 432) de novo intrachromosomal
alterations have been identified.
Conclusions: Array CGH should be considered an essential aspect of the genetic analysis of patients with
MCA/MR. In addition, in the present study three patients were mosaic for a structural chromosome
rearrangement. One of these patients had monosomy 7 in as few as 8% of the cells, showing that array
CGH allows detection of low grade mosaicisims.
C
hromosomal abnormalities are a major cause of mental
retardation and congenital malformations. Many chro-
mosomal defects are readily detected by standard or
high resolution karyotyping. However, at best, the resolution
of cytogenetic analysis is limited to about 5 to 10 Mb. It has
long been assumed that a considerable proportion of patients
with multiple congenital anomalies and mental retardation
(MCA/MR) have submicroscopic chromosomal imbalances,
not detectable by routine karyotyping. Such hidden abnorm-
alities have been detected at the subtelomeric regions in
around 5% of these patients.1–4 Following the introduction of
the principle of array comparative genomic hybridisation
(CGH),5 6 genome-wide high resolution analysis for DNA
copy number alterations became feasible. In analogy with
karyotyping, genome-wide array CGH has been termed
molecular karyotyping.7–9 The first papers by Vissers et al10
and Shaw-Smith et al11 reported as much as 15–24% of
segmental aneusomies in patients with idiopathic mental
retardation and dysmorphism. A few additional studies
reported detection rates between 10% and 25%.12–14 To
evaluate the clinical relevance of a chromosomal imbalance,
there is a need to collect genotype and phenotype information
in a large number of patients. This will allow the determina-
tion of the incidence and the genomic distribution of disease
causing imbalances and may reveal the underlying mechan-
isms causing chromosomal imbalances.
In this study we report array CGH data on a new series of
140 patients and review the findings of 292 previously
reported patients in order to determine the overall incidence
and clinical relevance of each of these chromosomal
imbalances. In addition, we provide the first evidence that
array CGH screening allows the detection of low grade
mosaicism for chromosomal aberrations.
METHODS
Selection of patients
This was a collaborative study between the genetic teams of
Leuven and Gent. Patients were selected for the study by
clinical geneticists from both teams. The study was approved
by the institutional review board and appropriate informed
consent was obtained from human subjects. Subjects had
mental handicap without known aetiology, but a chromoso-
mal aberration was suspected because of the association with
one or more major congenital malformation (such as
congenital heart defect, cleft palate, brain malformation,
and so on), or dysmorphism (three or more minor
anomalies), or both. Ages varied between one and 62 years,
with a mean age of 13.1 years. The number of males and
females was about equal. All patients had a normal karyotype
on G banding analysis at ISCN +550. The presence of a
Abbreviations: BAC, bacterial artificial chromosome; CGH,
comparative genomic hybridisation; CNV, copy number variation;
MCA/MR, mental retardation and multiple congenital anomalies; PAC,
P1 derived artificial chromosome; RTQ-PCR, real time quantitative
polymerase chain reaction
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subtelomeric abnormality was excluded by fluorescence in
situ hybridisation (FISH) or multiplex ligation-dependent
probe amplification (MLPA) in 31 of 140 patients. Genomic
DNA from each patient was isolated either from blood
lymphocytes or from cultured fibroblasts. When consent
could be obtained, full phenotypic descriptions of patients
with anomalies were submitted to DECIPHER (database of
chromosomal imbalance and phenotype in humans using
ensembl resources: http://www.sanger.ac.uk/PostGenomics/
decipher/).
Array CGH
Bacterial artificial chromosome (BAC) arrays were developed
from the 1 Mb clone set of the Sanger Institute which
contains 3431 BAC and PAC clones, as previously
described.8 15 16 In short, BAC and PAC (P1 derived artificial
chromosome) DNA was isolated from 1 ml bacterial cultures
and amplified by two rounds of degenerate oligonucleotide
primer polymerase chain reaction (DOP-PCR) using an
amino linked primer in the second PCR,15 and purified on
Multiscreen purification plates (Millipore Inc, Bedford,
Massachusetts, USA). Purified aminolinked PCR products
were spotted in duplicate or triplicate at a concentration of
250 ng/ml on three dimensional CodeLink Bioarray System
slides (Amersham Biosciences, Piscataway, New Jersey, USA)
with a Lucidea spotter (Amersham Biosciences) or a
QArrayMini spotter (Genetix). DNA (300 ng) was labelled
by a random prime labelling system (BioPrime Array CGH
genomic labelling system, Invitrogen, San Diego, California,
USA) using Cy3 and Cy5 labelled dCTPs (Amersham
Biosciences). Probe concentration and labelling efficiencies
were measured with a Nanodrop ND-1000 spectrophotometer
(Nanodrop Technologies, Rockland, Delaware, USA).
Following labelling, hybridisation, and washing of the slides,
arrays were scanned at 532 nm and 635 nm using a GenePix
4000B scanner (Molecular Devices) or a GMS 418 scanner
(MWG).
Image and data analysis
The scan images were processed with Imagene software
(Biodiscovery, El Segundo, California, USA) and further
analysed with an in-house developed and freely available
software tool, ‘‘arrayCGHbase’’ (http://medgen.ugent.be/
arrayCGHbase/).16 In brief, spot intensities were corrected
for local background and only spots with signal intensities at
least 1.5 times above background were included in the
analysis. Where useful, further normalisation of the data was
achieved by two dimensional Lowess normalisation using
Bioconductor software.17 Following this normalisation, the
values of the duplicates/triplicates on the array and the
duplicate experiments were averaged and a log2 value was
calculated. If signal intensity ratios among replicate spots
deviated by more than twice the overall standard deviation of
all intensity ratios, the spot was not analysed further. At least
95% of the spotted clones fulfilled these quality criteria. The
experiment was only scored successful if the standard
deviation of the log2 of the overall spot intensity ratios was
less than 0.096. Typically, this SD value for a combined
experiment is between 0.035 and 0.06. Clones that have been
identified in previous control hybridisations and other
studies as being polymorphic were excluded from the
analysis.8 18 Of the 3431 targets on the array, 57 autosomal
and eight X chromosomal clones are considered to be
polymorphic.
Two or more flanking targets exceeding a value of the
mean ¡ four times the SD of the log2 of all intensity
ratios for that hybridisation experiment were further
investigated to confirm the presence or absence of a genomic
imbalance. Single targets showing hybridisation intensity
ratios exceeding a value of ¡ [log2(3/2)–2*SD] were also
further validated. Validation was undertaken by metaphase
FISH for all potential deletions and both metaphase and
interphase FISH analysis for all potential duplications larger
than 2 Mb in size. Real time quantitative PCR was used to
confirm duplications smaller than 2 Mb in size. If in two or
more flanking clones the log2 of the combined intensity ratios
exceeded the threshold value of 46SD, FISH or real time
quantitative PCR experiments always confirmed the presence
of a chromosomal imbalance. If the intensity ratio exceeded
¡ [log2(3/2)–2*SD] at only one isolated clone in both
experiments, a false positive rate of one every seven patients
is observed.
FISH
Labelling of the DOP amplified BAC DNA that was used for
spotting the arrays was carried out by DOP-PCR on a
thermocycler (GeneAmp9700, Applera, Nieuwekerk a/d
Ijzer, Netherlands). The reactions were done in a total
volume of 50 ml containing 5 ml of 15 mM DOP 1, 2, 3
primermix, 5 ml of 106 PCR buffer w/o MgCl2, which is
specially designed for use with PlatinumH Taq DNA poly-
merase (Invitrogen), and 5 ml of 50 mM MgCl2. For the
dNTPs we used 1 ml of 10 mM dATP, dCTP, dGTP each, 0.7 ml
of 10 mM dTTP, 1 ml of 1 mM SpectrumGreenTM or
SpectrumOrangeTM dUTP (Vysis, Abbott Laboratories,
Abbott Park, Illinois, USA) or 5 ml of 106 dNTP mixture
containing 1 mM biotin-14-dCTP, 1 mM dCTP, 2 mM dATP,
2 mM dGTP, 2 mM dTTP in 10 mM Tris-HCl (pH 7.5), 1 mM
Na2 EDTA (Bioprime DNA labelling system, Invitrogen).
PlatinumH Taq DNA polymerase (Invitrogen) (0.5 ml), 2 ml of
the DOP amplified BAC DNA and H2O to 50 ml were added.
After initial denaturation at 95 C˚ for 10 minutes, the reaction
was as follows: 35 cycles of 95 C˚ for one minute, 60 C˚ for one
minute, 72 C˚ for one minute, and a final extension step of
72 C˚ for 10 minutes.
Purification of the PCR product was carried out with the
Qiaquick 8 PCR purification kit (Qiagen NV, Venlo,
Netherlands) using QIAvac 6S vacuum according to the
suppliers’ instructions.
In addition to the region-specific BAC clones used for
validation of array CGH results in patients with suspected
imbalance, a chromosome 7 centromere specific probe was
used for analysis of patient 19 with suspected monosomy 7
mosaicism (see Results). In all, 200 cells were screened for
this patient and a control sample by two independent
observers.
Before FISH, cells were air dried on slides and pretreated
with pepsin followed by fixation with a 1% free formaldehyde
solution and subsequent dehydration with ethanol. After
hybridisation O/N at 37 C˚, the slides were washed for one
minute in 0.46SSC/0.3% NP40 solution at 72 C˚, one minute
at 26 SSC/0.1% NP40 solution at RT, and one minute at 26
SSC. The cells were counterstained with DAPI and the slides
were mounted in Vectashield mounting medium (Vector
Laboratories, Burlingame, California, USA). The signal was
visualised by digital imaging microscopy with Cytovision
capturing software (Applied Imaging, Santa Clara, California,
USA). FISH was done as described.19
Real time quantitative PCR (RTQ-PCR)
The oligonucleotides were selected by using PrimerExpress
2.0.0 ABI Prism oligo design software (Applied Biosystems,
Lennik, Belgium). A penalty score less than 150 was used to
analyse the selected oligonucleotides further. The primers
and amplicon were separately checked to exclude any
repetitive sequences by using the BLAST program from the
NCBI browser (http://www.ncbi.nlm.nih.gov/BLAST/) and
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the repeatmasker program (http://www.repeatmasker.org/
cgi-bin/WEBRepeatMasker).
RTQ-PCR was carried out using the qPCR mastermix Plus
for SYBR Green I without UNG (Eurogentec, Liege, Belgium)
according to the manufacturer’s instructions. The final
volume of 25 ml contained 0.5 mM of both forward and
reverse primers, 12.5 ml of 26reaction buffer and 5 ml of DNA
solution in the range of 2 to 50 ng per reaction. Total genomic
DNA from human blood was purified by using an automated
version of the purification protocol using Chemagic Magnetic
Separation (Chemagen Biopolymer Technologie AG,
Baesweiler, Germany).
PCR was carried out in triplicate from each fraction using
50 C˚ for two minutes and 95 C˚ for 10 minutes, followed by 40
cycles of 95 C˚ for 15 seconds and 60 C˚ for 60 seconds. An 81
base pair DNA fragment within the p53 gene (forward: 59-
CCC AAG CAA TGG ATG ATT TGA-39 and reverse: 59-GAG
CTT CAT CTG GAC CTG GGT-39) was used as a control
amplicon (Eurogentec). Serial fivefold dilutions of this target
ranging from 100 ng to 0.16 ng per experiment served as a
standard quantitation curve.
RTQ-PCR was done with the locus-specific oligonucleotides
of interest on an ABI PRISM 7000 Sequence Detection
System (SDS) according to the manufacturer’s instruction
manual (Applied Biosystems, Lennik, Belgium). The ampli-
fication results and the melting curve were analysed with the
ABI Prism 7000 SDS software version 1.1 (Applied
Biosystems). The DNA levels were normalised to the gene
p53 and relative differences were calculated according to the
relative quantitation method.20
RESULTS
Array CGH findings in 140 patients with unexplained
MCA/MR
One hundred and forty patients with unexplained mental
retardation and features suggestive of a chromosomal
anomaly (for example, a major malformation or multiple
minor anomalies) were analysed on a 1 Mb BAC array. The
DNA from each patient was labelled and hybridised with
label swap versus the DNA of two other MCA/MR patients,
rather than using a ‘‘normal’’ reference sample. Dye swap
hybridisations for three patients in three hybridisations
reduces by half the number of experiments and the cost per
patient sample. This approach may be counterintuitive and
seem inappropriate in a diagnostic setting. However, the ideal
reference genome is non-existent owing to large scale copy
number variations between the genomes of different ‘‘nor-
mal’’ individuals.21 22 To mask benign copy number variation
(CNVs), other groups have used pooled DNA of from seven to
10 different male or female subjects as reference material.11–14
For frequently occurring CNVs, intensity ratios will be
reduced. If a CNV were present in 50% of the population,
the intensity ratio difference at this locus would be reduced
by half. Rather than improving the outcome, this result
complicates data interpretation. One disadvantage of using
patients as reference in three hybridisations could be that
similar imbalances in two or three of the patients would
result in equal intensity ratios for the affected region and
potentially mask imbalances. However, the finding that the
recurrence of a similar chromosomal imbalance in two
patients with idiopathic MCA/MR is less than 1% (see below)
makes the risk that a similar imbalance would occur in two
and three independent patients smaller than, respectively, 1/
104 and 1/106.
A chromosomal imbalance was detected in 28 patients
(20.1%). An overview of all imbalances is shown in fig 1, and
array CGH profiles for aberrant chromosomes are presented
as supplementary information. Table 1 summarises the
genotype and phenotype of these 28 patients. For eight
patients the imbalance spanned more than five clones
(.5 Mb in size), for 10 patients between two and five clones
(1–8 Mb in size), and for 10 patients the imbalance was only
a single clone (,3 Mb). In two patients there was evidence of
mosaicism for a structural chromosomal aberration and in
one patient a low grade mosaicism for chromosome 7
monosomy was detected (see below). In 17 of 24 patients
in whom the parents could be investigated the chromosomal
imbalance was de novo by either FISH (deletions or
duplications larger than 3 Mb) or quantitative PCR (qPCR)
(small duplications). While none of the imbalances smaller
than 5 Mb could be detected by high resolution karyotyping,
three large deletions (in patients 7, 12, and 15) and two
mosaics (in patients 14 and 18) became apparent after
retrospective analysis of the karyotype. Eight imbalances
(5.7%) involved a subtelomeric region.
All de novo alterations can be considered causal for the
MCA/MR phenotype observed in the patients. For four of the
28 patients with a chromosomal imbalance, the parents were
not available for genotyping. One of these (patient 1) had a
large deletion on 1p36.2 spanning multiple clones. As the
observed phenotype in this patient resembles that of patients
with known 1p terminal deletions, this imbalance was
considered causal. For patients 3, 19, and 20 only one or
two clones were abnormal making the causal relation
between genotype and phenotype difficult to determine.
For seven of the 28 patients the imbalance (three
duplications and four deletions) was inherited from one of
the parents. These parents were phenotypically normal with
the exception of the father of patient 27, who had mild
learning disabilities, and the mother of patient 7, who was
similarly affected as the daughter. Patient 27 presented with
cleft lip and palate, mild learning difficulties, and a truncus
arteriosus. A duplication on chromosome 22q11.2 was
detected in this girl and her father. In view of previous
reports describing 22q11.2 duplications (including those
inherited from normal parents), we assume a direct relation
between the 22q11.2 duplication and the observed phenotype
in this patient. Patient 10 and one of two imbalances in
patient 7 have been listed as polymorphic in the Toronto
polymorphism database.21 In patient 7, the larger deletion on
chromosome 5 spanning between 6.8 and 11.8 Mb was also
present in the similarly affected mother. Hence this deletion
is likely to be causal for the phenotype. In patient 5, the
duplicated region in the healthy father and son contains only
a single gene, the glycogen branching enzyme (GBE1);
dosage effect for this gene seems a rather unlikely cause. In
patients 6, 17, and 28, single clone imbalances are inherited
and the causal relation between genotype and phenotype
remain to be determined.
In summary, we consider that at least 19 of the 28 observed
imbalances are causal for the MCA/MR in the patients.
Cytogenetic features of (low grade) mosaic
chromosomal imbalances
A further interesting observation in this study was the
finding of three mosaics. In patient 16, array CGH revealed
increased average intensity ratios for a 12 Mb region
compatible with a duplication spanning the long arm of
chromosome 13 from band 13q31.3 to 13q33.1 (fig 2A). The
average log2 of the intensity ratio values of the abnormal
clones was 0.38. As the theoretical intensity ratio of a
duplication is log2 (3/2) or 0.58, the estimated mosaicism
level is 0.38/0.58 or 65%. FISH analysis confirmed the
duplication to be present in 60% of cultured lymphocytes
(fig 2B).
In patient 14, standard array CGH revealed a 5 Mb deletion
at 11q22.1–23.1. FISH with clone RP11-87N22 confirmed the
deletion at the 11q22.1 locus in all cells. Forty clones flanking
Array CGH in patients with MCA/MA 627
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this deletion (14 proximal and 26 distal to the deleted
segment) showed a mean intensity ratio of 0.21, suggesting a
duplication of the adjacent region at 11q21-qter in approxi-
mately 35% of the cells (fig 2C). FISH with clone RP11-
744N12 located within this presumed duplicated region
showed a translocation of 11q21-qter onto chromosome 9
in 6% of the cells, in contrast to the estimated 35% (fig 2D).
As this FISH analysis was performed on lymphocytes
following stimulation with phytohaemagglutinin, and DNA
used for array CGH was extracted from uncultured lympho-
cytes, we assumed that culturing resulted in clonal selection
of the normal cells. FISH on uncultured lymphocytes
confirmed this hypothesis and showed three signals of
RP11-744N12 in as many as 25% of the nuclei of uncultured
lymphocytes.
Array CGH analysis on patient 9 revealed an average
intensity ratio of 20.0496 for the clones from chromosome 7
(fig 2E). The level of mosaicism is calculated to be 5%.
Interphase FISH analysis by two independent observers using
a centromere 7 specific probe revealed a single signal in 10.5%
of the nuclei of peripheral white blood cells of the patient while
in a control sample a single signal was observed in only 3.5% of
the nuclei. The difference between these two proportions was
significant (p,0.01), thus confirming the presence of the
monosomy in approximately 8% of the patient’s white blood
cells. This finding can probably be explained by the presence of
a (pre)malignant clone in this patient.
Review of published reports on MCA/MR patients with
submicroscopic imbalances
To obtain insight into the incidence, characteristics, and
genomic distribution of imbalances detected by array CGH in
MCA/MR patients, all published genomic imbalances were
reviewed (fig 1 and table 2).10–14 From a total of 192 patients
screened by arrays at ,1 Mb resolution, 41 imbalances were
detected (21%), of which at least 20 (10%) were de novo. Of
the 192 patients, 113 were screened for subtelomeric
imbalances before array CGH. The number of interstitial
imbalances was 35 (18%), of which at least 17 were de novo
(8.8%). In addition, de Vries et al analysed 100 patients
previously shown not to carry subtelomeric imbalances using
an array covering the full genome and detected de novo
alterations in 10 patients.12 Five imbalances were likely to be
causal, but parents were not available for analysis. Of these
15 imbalances, five were smaller than 1 Mb.
Figure 1 shows that the imbalances were more or less
scattered across the genome and appeared mostly randomly
distributed over all chromosomes. Some chromosomal
regions appeared non-randomly involved. Interstitial aberra-
tions at chromosome 1p36 were detected in two patients in
the present study and in three published array CGH cases.
Hence, in addition to the 1p36 terminal deletion syndrome—
considered to be the most common subtelomeric microdele-
tion syndrome23—interstitial subtelomeric deletions also
appear to be common. At two loci (1q21.1 and 5q35.1), both
Figure 1 Overview of all published interstitial submicroscopic imbalances detected by array-CGH in patients with mental retardation and multiple
congenital anomalies (MCA/MR). Microdeletions and duplications identified in this study are represented by, respectively, red and green bars.
Microdeletions and duplications identified by previous array CGH studies10–14 are indicated by, respectively, the orange and the blue bars. Polymorphic
variants from de Vries et al12 are not shown.
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a duplication and a deletion were observed. Possibly these
sites may mark novel microdeletion syndromes caused by
recurrent non-homologous recombination in low copy
repeats. Of particular interest is the finding of a familial
duplication on 22q11.2 in this study, as well as in three
previous reported cases (two de novo and one case of
unknown origin), further suggesting the recurrent nature of
this duplication and the variable phenotypic effect.
DISCUSSION
This study is the largest series of patients reported who have
been screened for chromosomal imbalances with a 1 Mb
resolution BAC array. In a total of 140 patients, 28
chromosomal imbalances were detected (20%). These
included seven duplications, 18 deletions, and three unba-
lanced translocations. To determine the causal role of these
chromosomal aberrations, parents were investigated in 24 of
28 patients. In addition, the Toronto database of normal
variants was consulted. About three quarters (17/24) of the
observed chromosomal aberrations were de novo and not
reported before as a normal variant. In one patient for
whom the parents could not be tested, available phenotypic
data for similar published cases indicated that the
genotype could explain the observed phenotype, and in one
patient with inherited deletion the mother was equally
affected. This brings the total of clinically relevant imbal-
ances to 19. Taking into account these data and excluding
those subtelomeric imbalances that could have been detected
by FISH or MLPA/MAPH analysis, our study has identified 11
clinically relevant imbalances (8%) undetectable by karyo-
typing and subtelomeric screening. This is in accordance with
previous findings of 10–15% causal interstitial submicro-
scopic imbalances in patients with MCA/MR.10–14 Imbalances
identified thus far in MCA/MR patients have been positioned
on the human genome map in order to assess their genomic
distribution and to detect overlapping regions. This map
further confirms that most imbalances are scattered across
the genome.
From our data and data from other published reports it has
become clear that the clinical application of array CGH poses
new challenges. While it is assumed that de novo alterations
result in the observed phenotype, only the recurrent associa-
tion of imbalances with specific phenotypic features will
reinforce this causal relation. Hence, it will be essential to
collect genotypic and phenotypic information on a large
number of MCA/MR patients. In contrast to de novo
alterations, many chromosomal imbalances are inherited.
Although it is likely that frequently occurring genomic CNVs
may not have major disease causing phenotypic effects, rare
variants, such as the six familial inherited imbalances
detected in this study, should be evaluated with care. In
particular, imbalances of regions which are recurrently
involved in familial transmission from a normal parent to
affected children will pose specific problems for genetic
counselling, as illustrated by the 22q11.2 duplication. This is
in line with previous observations that 22q11 duplications
result in diverse phenotypes from normal to mild to severe,
and sharing a tendency for velopharyngeal insufficiency with
DiGeorge/VCFS (velo-cardio-facial syndrome) but with other
distinctive characteristics as well.24 25 The 22q11 duplication
syndrome may hallmark a novel paradox encountered by
molecular karyotyping, as the causal relation between a
chromosomal anomaly and an associated phenotype becomes
blurred. Hence, imbalances inherited from phenotypical
normal parents may contribute to the phenotype through
variable penetrance or expressivity, or both, through epige-
netic effects, or by uncovering a recessive mutation on the
non-deleted allele. To understand the involvement of these
variations in the observed phenotypes, it will be necessary not
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only to collect benign variation in the genome and informa-
tion on de novo imbalances associated with disease pheno-
types, but also to collect both genotype and phenotype
information from patients with familial inherited imbalances
and phenotypically normal parents. To start this data
collection, both genotype and phenotype data from all
patients who consented was submitted at the DECIPHER
database (http://www.sanger.ac.uk/Postgenomics/decipher/).
Segmental chromosomal imbalances in mosaic state are
causal in several MCA/MR syndromes.26 The present study
illustrates that array CGH may detect segmental chromoso-
mal imbalances which may be overlooked in standard
karyotyping when a small number of cells is analysed or
when the abnormality is too small to arouse suspicion. A
remarkable observation in one of the mosaics was that
phytohaemagglutinin stimulation of lymphocytes and sub-
sequent short culture apparently induced a selective growth
advantage for the normal cells. Clearly, such culture effects
can bias the final cytogenetic observations, as was observed
in patient 14. Presently a theoretical model is being developed
which should enhance the sensitivity for the detection of low
grade mosaicism. Clearly, the presence of a large deletion
present in as few as 5% of cells can easily be detected. The
ability to detect low grade mosaics will allow the detection of
chromosomal aneuploidies in highly contaminated speci-
mens such as aborted fetuses27 and in the analysis of tumours
and leukaemias.28
In all reports, including this study, the number of deletions
(57) was greater than the number of duplications (24). This
may have both a technical and a biological component.
Figure 2 Cytogenetic analysis of patient 16 (panels A and B), patient 14 (panels C and D) with segmental chromosomal mosaicisms, and patient 9
(panel E) with a mosiacism monosomy of chromosome 7. (A) Partial molecular karyotype enlarging the ratio profiles for chromosome 13; in the x axis
clones are ordered from the centromere to the q-arm telomere, and the y axis shows the log2 transformed intensity ratios at each locus. Red lines
indicate the threshold for clone deletion or duplication (¡4*SD). (B) Fluorescence in situ hybridisation (FISH) with PAC 1091O16 confirmed that the
duplication at 13q32The duplication was present in 60% of the cultured lymphocytes. (C) Partial molecular karyotype enlarging the ratio profiles for
chromosome 11. On the x axis clones are ordered from the p-arm telomere to the q-arm telomere and the y axis shows the log2 transformed intensity
ratios at each locus. Red lines indicate the threshold for clone deletion or duplication (¡4*SD). (D) The duplication at 11q24.3 was confirmed with
clone BAC 744N12 and was the result of a translocation between 11q and 9q. FISH on cultured and uncultured lymphocytes showed the duplication to
be present in, respectively, 6% and 25% of the cells. (E) Molecular karyotype showing the ratio profiles for the chromosomes 1 to 22, X, and Y.
Chromosome 7 is positioned between the two vertical lines, and shows log2 transformed intensity ratios with an average of 20.05.
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Technically, most threshold algorithms may favour more
false negatives for duplication events as compared with
deletion events. Most threshold algorithms determine cut
offs for both deletions and duplications at equal distance
from the mean of all intensity ratios. As the intensity ratios
for chromosomal deletions are more distant from the mean
(ratio of 1/2) as compared with the intensity ratios observed
for duplications (ratio of 3/2), inevitably there is a greater
chance that some duplications may be missed. Second, there
may be a biological bias. Duplications generally result in a
milder phenotype; therefore there may be a selection bias in
this patient population. In addition, the frequency of random
duplication events in the human genome may be lower than
the frequency of deletion events. Van Ommen29 estimated the
frequency of deletion events to be one in every eight births,
and the duplication frequency one in every 50 births. This
suggests that the number of deletion events is about sixfold
greater than the number of duplication events. In patients
with MCA/MR, deletions outnumber duplications by approxi-
mately twofold.
In conclusion, we confirm that a high percentage of MCA/
MR cases hitherto considered idiopathic is caused by
submicroscopic chromosomal imbalances. Consequently,
screening of selected patients with normal karyotypes seems
desirable and feasible. The availability of commercial plat-
forms and improved hybridisation schemes resulting in
reduction of costs for these analyses opens the way for
implementing array CGH in routine diagnostic analysis.
At present it remains unclear what resolution of the array
will be optimal for screening MCA/MR patients. Higher
resolution arrays may reveal larger numbers of small
chromosomal imbalances. However, the finding of only
10% of de novo imbalances in a cohort of 100 patients by a
full coverage array may indicate that higher resolution
does not necessarily increase the diagnostic yield. More
studies using high resolution arrays are needed to
compare the incidence of small imbalances in different
patient populations. Nevertheless, using a 1 Mb resolution
array, some imbalances smaller than 1 Mb are being
missed. In addition, the false positive rate may be lowered,
especially if the identification of imbalances is based on
intensity alterations of three or more aberrant flanking
clones.12 Considering the large percentage of inherited
chromosomal imbalances, establishing both benign copy
number variations in the human genome as well as
developing a comprehensive morbid map of the human
genome will be of major importance for understanding which
imbalances are causative.
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This report presents the detection of a heterozygous deletion at
chromosome 12q14 in three unrelated patients with a similar
phenotype consisting of mild mental retardation, failure to
thrive in infancy, proportionate short stature and osteopoikilosis
as the most characteristic features. In each case, this interstitial
deletion was found using molecular karyotyping. The deletion
occurred as a de novo event and varied between 3.44 and
6 megabases (Mb) in size with a 3.44 Mb common deleted
region. The deleted interval was not flanked by low-copy
repeats or segmental duplications. It contains 13 RefSeq genes,
including LEMD3, which was previously shown to be the causal
gene for osteopoikilosis. The observation of osteopoikilosis
lesions should facilitate recognition of this new microdeletion
syndrome among children with failure to thrive, short stature
and learning disabilities.
C
lassical cytogenetic analysis has played an essential role
in the discovery of recurrent segmental deletions in
patients with clinically recognisable mental retardation
such as Prader–Willi, Miller–Dieker, Langer–Giedion and
velocardiofacial syndromes.1 The subsequent delineation of
commonly deleted segments and mapping of small atypical
deletions have allowed the identification of genes responsible
for the major clinical features of these contiguous gene deletion
syndromes.2 Recently, molecular karyotyping was proven to be
a more powerful tool in detecting submicroscopic deletions or
duplications in patients with so-called idiopathic mental
retardation with or without congenital malformations.
Molecular karyotyping studies have shown that in about 10%
of these cases segmental imbalances can be found.3–9 Using this
new genome-wide screening technology, new disease genes can
be identified, as illustrated for the CHD7 gene in CHARGE
syndrome.10 Very recently, some new microdeletion syndromes
were identified using molecular karyotyping.11–13
Here, we report on three unrelated patients with de novo
12q14 microdeletions. They share osteopoikilosis, short stature
and learning disabilities as common phenotypic features. In
two cases the deletion was approximately 6 megabases (Mb) in
size whereas in the third patient a 3.44 Mb deletion was
detected.
The first proband (03g1858) is a girl born at term with a birth
weight of 2060 g. Pregnancy and delivery were uneventful. At
the age of 6 months, she presented with failure to thrive and by
the age of 1 year, length, weight and head circumference were
all far below the third centile. Work-up for this failure to thrive
only revealed hypertension, for which she received medication.
The diagnosis of Russell-Silver syndrome was considered at
that time. The girl also showed delayed neuromotor develop-
ment and experienced learning difficulties requiring an
individualised programme at school. Clinical evaluation at the
age of 16 years revealed proportionate short stature with a
weight of 31.8 kg (24 SDs), height of 131.5 cm (26.2 SDs),
span of 131 cm and head circumference of 49 cm (24.4 SDs).
The face was mildly dysmorphic with synophrys, mild
hypertelorism, broad and high nasal bridge, micrognathia and
maxillary overbite. These clinical features were not reminiscent
of Russell-Silver syndrome. Imaging studies revealed the
presence of ectopic kidneys, and an aortogram showed on each
side two renal arteries with an aberrant origin. In addition,
malrotation of the small bowel, a medially positioned spleen
and an unusually shaped (rectangular) liver were found.
Radiographic evaluation showed multiple osteopoikilosis
lesions in the pelvis, shoulders, wrists, hands and feet (fig 1A).
The second female proband (D0502619, figure 1B,C) was
born at term with a weight of 2300 g. The pregnancy was
complicated by oligohydramnios. The postnatal course was
uneventful. Early in infancy very poor growth and development
became apparent. At the age of 4 years she was diagnosed with
scoliosis, type 1 Arnold-Chiari malformation and ultimately
syringomelia requiring a shunt. She also had a release for a
tethered spinal cord. Reflux nephropathy with small kidneys,
mild hypertension and diabetes mellitus were diagnosed in
childhood. In school, mild learning problems became apparent,
and therefore she was put on an individualised education plan.
At the age of 14 years she presented with complaints of tingling
pain in the medial part of her right foot. Clinical evaluation
revealed a weight of 51.3 kg (mean for age), height of 142.3 cm
(23.5 SDs) and head circumference of 53.3 cm (20.66 SDs).
Her face was round with rather deep-set eyes, bushy eyebrows
and thin lips. (fig 1B,C). A thoracolumbar scoliosis was noted.
The skin showed several areas of increased pigmentation. Mild
swelling without other inflammatory signs was present on the
right foot. The gait pattern was somewhat antalgic.
Radiographic evaluation revealed numerous osteopoikilosis
lesions in the distal part of the tibia and fibula as well as in
the right foot. In addition, the second right metatarsal showed
a thickened and irregular cortical lesion suggestive of melor-
heostosis at the diaphysis. At the age of nearly 16 years, she is
now functioning at the level of a 10-year-old child. She is quite
sociable and tends to be very articulate and repetitive.
The third patient (#4818) is the male product of the first
pregnancy of an unrelated 22-year-old mother and 35-year-old
father. The pregnancy was complicated by hyperemesis. There
were no adverse exposures. The family history was non-
contributory. Delivery was at term with weight at the third
centile and length at the tenth centile. The boy failed to thrive
during the first year. At age three years six months, all growth
measurements were below the third centile, and development
was a year delayed. Growth hormone levels and bone age were
normal. At age four, he was found to have delays in fine motor
Abbreviations: FISH, fluorescence in situ hybridisation; Mb, megabase
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skills and speech. Six secondary teeth were missing on dental
radiographs. After sustaining a fracture of the right tibia, he
developed clawing of the toes and electromyogram findings
suggestive of sciatic nerve injury. Radiographs documented
osteopoikilosis lesions within multiple bones. When seen at 12
years of age, he was noted to have mild developmental delay,
with difficulties in spelling and reading. He was tiny, with all
growth measurements below the third centile. His face was
triangular with widely spaced eyes. There were yellowish raised
areas on the skin overlying the upper chest and flank.
Trichothiodystrophy was considered as a diagnosis, but his
hair was normal. He was reported to have a tremor that
increased with writing. The patient was seen again at 18 years
of age. His final height of 152 cm and weight of 41 kg were
both below the third centile. He described a slow increase in
tremor, most marked upon arising or intention. His overall
health had been good, and he had achieved a normal puberty.
He was entering grade 12, taking applied mathematics, and
having problems with English.
The microdeletion in the first proband (03g1858) was
identified during the course of mapping the gene for
osteopoikilosis.14 The patient showed loss of heterozygosity for
a stretch of markers in the linkage interval, which resulted in a
considerable reduction of the critical region and finally led
(through a candidate gene approach) to the identification of
LEMD3 as the causal gene for osteopoikilosis. The deletion was
confirmed with fluorescence in situ hybridisation (FISH) using
BAC clone RP11-305O6, as described by Van Roy et al.15
Breakpoints were further delineated using array CGH as
described by Menten et al16 with a custom tiling path array for
chromosomal bands 12q14–12q15. BAC clones were selected
based upon the May 2004 human genome project assembly
(http://genome.ucsc.edu/) (table 1, appendix).
After publication of the first patient, a second patient with a
similar phenotype was identified. FISH with BAC clones RP11-
305O6 and RP11-361O1 confirmed the presence of a micro-
deletion encompassing LEMD3 on chromosome 12. As in the
first proband, the size of the deletion and the position of the
breakpoints were determined by array CGH using a custom
tiling path array with overlapping BAC clones (fig 2). The size
of the deletion in the first two cases was similar (about 6 Mb)
with an overlap of about 5.3 Mb. The genomic position of the
deletion in patient 1 was slightly more telomeric than that in
patient 2. Karyotyping and FISH of the parents of patients 1
and 2 yielded normal results, indicating that both deletions
occurred de novo.
The microdeletion in the third patient (#4818) was identified
during a study of 100 children with idiopathic mental
retardation and normal standard chromosomal analysis, using
Affymetrix GeneChipH Human Mapping 100K arrays.9
Breakpoints were mapped to SNP rs10506536 (63342649 base
pairs) and SNP rs10492198 (66780095 base pairs), indicating a
3.44 Mb deletion. Affymetrix GenechipH analysis of the parents
yielded normal results, indicating that this deletion also
occurred de novo. The deletion in the child was confirmed by
FISH using BAC RP11-91K23. This deletion is smaller but lies
entirely within the 5.3 Mb region that was deleted in both
patients 1 and 2 (fig 2).
Segmental duplications or low copy repeats have been shown
to play an important role in the formation of recurrent
microdeletion syndromes by non-allelic homologous recombi-
nation.17–20 However, no evidence of segmental duplications or
low-copy repeats was found near any of the six breakpoints in
these three patients. Microdeletions may also occur without
involvement of low copy repeats.12 21–23 Recent reviews estimate
that only 25–50% of copy-number variants are associated with
segmental duplications.24 Recurrent microdeletions that are not
associated with low-copy repeats usually have different break-
points in each case. They most likely result from breakage with
subsequent nonhomologous endjoining. Given the apparent
absence of low copy repeats near the 12q breakpoints described
here, we suspect that a mechanism of nonhomologous end-
joining may be responsible for occurrence of the microdeletions
in our three cases.
In 1995, Jurenka and Van Allen reported a patient with
mental retardation, short stature and a mixed sclerosing bone
dysplasia reminiscent of melorheostosis.25 We suspect that this
patient may have the same microdeletion as found in our three
probands. Unfortunately, no DNA from this patient was
available to test this hypothesis.
The similar phenotype in our three probands is remarkable.
All three patients had a low birth weight and presented in
infancy with failure to thrive. They subsequently showed
delayed neuromotor development and finally mild mental
retardation. They do not show a remarkable facial dysmorph-
ism but all have a proportionate short stature with osteopoi-
kilosis lesions on skeletal radiographs. One patient
(#D0502619) developed a melorheostosis lesion in the foot.
We have shown in previous studies that loss-of-function
mutations in the LEMD3 gene can result in osteopoikilosis
and/or melorheostosis lesions.14 26 However, failure to thrive,
short stature and mental retardation are not observed in
patients with either osteopoikilosis or melorheostosis. These
findings must therefore be the result of haploinsufficiency for
other contiguous genes in the microdeletion interval. In the
common deleted region two interesting genes (HMGA2 and
GRIP1) reside, which may account for these additional clinical
problems in our patients (fig 2).
HMGA2 codes for an architectural factor belonging to the
high-mobility group (HMG) of proteins. It is characterised by
three conserved DNA-binding domains, AT hooks and an acidic
C-terminal tail. This gene product is involved in DNA packaging
and plays an important role as a transcription factor in gene
regulation.27 Recently, HMGA2 was described as the putative
causal gene in a patient with overgrowth, lipomas and a de
novo pericentric inversion of chromosome 12.28 Battista et al
reported a murine model with a constitutively expressed
truncated form of Hmga2, which led to gigantism associated
with lipomatosis. The authors proposed that disruption of the
Hmga2 gene led to upregulated expression.29 Disruptions and
A B C Figure 1 Clinical and radiographic features
of the microdeletion syndrome. (A)
Radiograph of the pelvis in patient 03g1858
showing multiple osteopoikilosis lesions in
the proximal parts of the femurs and pubic
bones. Facial phenotype of patient
D0502619 with anteroposterior (B) and
lateral (C) view (patients 03g1858 and
#4818 refused clinical photographs).
Parental/guardian informed consent was
obtained for publication of this figure.
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rearrangements of HGMA2 leading to aberrant gene expression
are a frequent observation in lipomas and other benign
mesenchymal tumours.30–37 Overexpression has also been
reported in malignant tumours.38 Interestingly, Zhou et al.
reported a ‘‘pygmy’’ phenotype in Hmga22/2 murine models,39
with heterozygous mice displaying a milder phenotype (80% of
the weight of wild-type mice).40 Taken together, these data are
consistent with an important role for HMGA2 in growth. Hence,
haploinsufficiency of this gene may result in short stature as
observed in our patients. To test this hypothesis, a series of
patients with idiopathic proportionate short stature will be
tested for loss-of-function mutations in the HMGA2 gene.
Glutamate receptor interacting protein 1 (GRIP1) is a good
candidate gene for mental retardation. GRIP1 is highly
expressed in adult human and fetal brain as well as in other
organ systems. The gene produces three different transcripts by
alternative splicing and contains seven highly conserved
domains. All GRIP1 products contain the PDZ domain, which
is important in synaptic function.41 GRIP1 proteins localise
through their PDZ domains to a-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid (AMPA) receptors in cultured
rat hippocampal neurons.42 43 These AMPA receptors mediate
synaptic transmission through glutamate, the major excitatory
neurotransmitter in the central nervous system. GRIP1 is
implicated in targeting AMPA receptors to the synapse.42 44 45
GRIP1 is also involved in the induction of long-term potentia-
tion in rat hippocampal mossy fibres.46 In addition to their role
in glutamergic synaptic transmission, GRIP1 products also
localise to GABAergic synapses in rat hippocampal cultures and
intact rat brain.47 48 Homozygous Grip1 knockout mice die as
embryos.49 The heterozygous Grip1 knockout mouse phenotype
has not yet been reported. The observations that GRIP1 codes
for a non-redundant protein that it is highly expressed in fetal
and adult human brain, and involved in glutamergic synaptic
transmission, support the possibility that GRIP1 haploinsuffi-
ciency caused the learning problems in our patients.
Table 1 BAC clones used for breakpoint detection in patients 1 and 2, with their name, sanger name, chromosome, start position
and end position according to the NCBI 36 genome assembly
Name Sanger name Chromosome Start (base pairs) End (base pairs) Patient 1 Patient 2
RP11-103L8 bA103L8 12 60326906 60482957 + +
RP11-96F13 bA96F13 12 60399378 60556846 + +
RP11-402I16 bA402I16 12 60470226 60639036 + +
RP11-196A13 bA196A13 12 60516544 60670139 + +
RP11-15P10 bA15P10 12 60592183 60768715 + +
RP11-542G14 bA542G14 12 60637601 60804185 + +
RP11-155D5 bA155D5 12 60695975 60861269 + +
RP11-120M24 bA120M24 12 60829050 60980979 + +
RP11-97A6 bA97A6 12 60917552 61052698 + +
RP11-169M9 bA169M9 12 60920103 60948010 + +
RP11-467D14 bA467D14 12 60966290 61162052 + 2
RP11-142E5 bA142E5 12 61085454 61271298 + 2
RP11-151H22 bA151H22 12 61221704 61367847 + 2
RP11-570O18 bA570O18 12 61280315 61431623 + 2
RP11-131G23 bA131G23 12 61343791 61525936 + 2
RP11-538D3 bA538D3 12 61529122 61684800 + 2
RP11-24L23 bA24L23 12 61634279 61805538 2 2
RP11-263K23 bA263K23 12 61706479 61872677 2 2
RP11-61L21 bA61L21 12 61883235 61951183 2 2
RP11-105I10 bA105I10 12 61907586 62065780 2 2
RP11-52P5 bA52P5 12 62021250 62183689 2 2
RP11-267F23 bA267F23 12 62033781 62189805 2 2
RP11-134D22 bA134D22 12 62196683 62347713 2 2
RP11-272A21 bA272A21 12 62218641 62371090 2 2
RP11-415I12 bA415I12 12 62349962 62538439 2 2
RP11-367H3 bA367H3 12 62470168 62644125 2 2
RP11-274J7 bA274J7 12 62508196 62670790 2 2
RP11-456A6 bA456A6 12 62577649 62745265 2 2
RP11-196H14 bA196H14 12 62738094 62928731 2 2
RP11-290I21 bA290I21 12 62854244 62854997 2 2
RP11-444B24 bA444B24 12 66740902 66931728 2 2
RP11-71J4 bA71J4 12 66926693 67077364 2 +
RP11-81H14 bA81H14 12 67059831 67208966 2 +
RP11-185H13 bA185H13 12 67160267 67368737 2 +
RP11-254B13 bA254B13 12 67191207 67347334 2 +
RP11-531F4 bA531F4 12 67255471 67462087 2 +
RP11-450G15 bA450G15 12 67366710 67543065 2 +
RP11-410I6 bA410I6 12 67507773 67668188 2 +
RP11-249J13 bA249J13 12 67574683 67726286 2 +
RP11-43A22 bA43A22 12 67681180 67830736 + +
RP11-324P9 bA324P9 12 67816914 68000647 + +
RP11-73J11 bA73J11 12 67862072 68020699 + +
RP11-426B12 bA426B12 12 67926203 68135266 + +
RP11-159A18 bA159A18 12 68032940 68179706 + +
RP11-23C15 bA23C15 12 68135291 68315468 + +
RP11-15L3 bA15L3 12 68217524 68403913 + +
RP11-161M18 bA161M18 12 68369051 68562065 + +
RP11-21I1 bA21I1 12 68442353 68627676 + +
RP11-21C8 bA21C8 12 68508458 68666217 + +
RP11-384F11 bA384F11 12 68610540 68808607 + +
RP11-60E14 bA60E14 12 68706960 68858931 + +
+, Presence of two copies; 2, the BAC clone is deleted according to the array CGH profile.
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We conclude that we have identified a newly recognisable
microdeletion syndrome involving chromosome 12q14. The
clinical phenotype is mainly characterised by mild mental
retardation, low birth weight with failure to thrive in early
infancy and proportionate short stature. The osteopoikilosis
lesions on skeletal radiographs are the most distinguishing
feature of this microdeletion syndrome that should facilitate
recognition of this peculiar disorder among children with
mental retardation and growth failure.
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ABSTRACT
Deletions involving the long arm of chromosome 18 have been
reported in many patients. Most of these deletions are localized in the
telomeric region and are detectable by standard cytogenetic analysis.
However, smaller and interstitial deletions leading to a recognisable
phenotype and residing in the region on chromosome 18q12.3 have
also been identified. Using array CGH, we detected an interstitial
deletion of only 1.8 Mb in size in chromosomal band 18q12.3. The
phenotype of this proband corresponded very well with that observed
in other reported cases with a structural monosomy of 18q12.3.
Further characterization of the deletion allowed us to determine a
critical region for the del(18)(q12.1q21.1) syndrome.
1 INTRODUCTION
ArrayCGH has been proven to be very helpful in (1) the
identification of submicroscopic chromosomal aberrations leading
to mental retardation and congenital abnormalities (MR/MCA)
[1-5],(2) the characterization of new microdeletion syndromes [6-
9] and (3) the identification of genes responsible for MR/MCA
syndromes 10. To the best of our knowledge, only one critical
region in a recurrent deletion syndrome has thusfar been delineated
using arrayCGH [11]. Most recurrent microdeletions are flanked
by Low Copy Repeats (LCRs), leading to similar breakpoints in
all affected patients and hampering in this way the identification
of the responsible critical genes. Recurrent interstitial deletions
not mediated by LCRs are less common. Deletions involving the
long arm of chromosome 18 have been reported in many patients.
Most of these deletions are telomeric deletions and are detectable
by standard cytogenetic analysis. However, smaller, interstitial
deletions, encompassing chromosome band 18q12.3, and parts
of neighbouring bands, have also been identified [12-23]. All
these cases with microscopic detectable interstitial deletions share
similar clinical features, including mental retardation, mild facial
dysmorphism and abnormal behaviour. Here we describe a boy with
typical features of the del(18)(q12.1q21.1) syndrome due to a 1.8
Mb deletion within chromosomal band 18q12.3.
∗to whom correspondence should be addressed
2 METHODS
2.1 Cytogenetic analysis and FISH
Analysis of G-banded metaphase chromosomes was performed on short-
term lymphocyte cultures using standard procedures. FISH was performed
as described [24].
2.2 Array CGH analysis
DNA was isolated from total blood using the Puregene Genomic DNA
Purification Kit (Gentra Systems), according to the manufacturer’s
instructions. Using random prime labelling, 500 ng of patient and
control female DNA was labelled with Cy3 and Cy5 (BioPrime Array
CGH Genomic Labelling System, Invitrogen) and subsequently purified
(Microspin G-50 columns, Amersham Biosciences). The labelled fragments
were suppressed with 150µg fluorometric QC Cot1-DNA (Invitrogen)
and 400µg yeast tRNA, and resuspended in 60µl hybridisation buffer
at 37◦C (50% formamide, 10% dextran sulphate, 0.1% Tween 20, 2x
SSC, 10 mM Tris pH 7.4). In-house produced 1 Mb resolution BAC
arrays consisting of 4048 clones spotted in triplicate on CodeLink Activated
slides (Amersham Biosciences) were prehybridised at 37◦C during 1h using
100µg fluorometric QC Cot1-DNA (Invitrogen) and 150µg herring sperm
DNA, resuspended in 120µl hybridisation buffer. After removal of the
prehybridisation mixture, patient and control DNA was simultaneously
hybridised for 48h at 37 ◦C. The slides were washed in 1x PBS/0.05%
Tween 20 for 10 min at room temperature, 50% formamide/2x SSC for
30 min at 42◦C and finally 1x PBS/0.05% Tween 20 for 10 min at
room temperature. After centrifuge drying, the slides were scanned using
a GMS 418 Array Scanner (MWG). The scan images were processed
with Imagene software (Biodiscovery) and further analysed with our
in-house developed and freely available software tool arrayCGHbase
(http://medgen.ugent.be/arraycghbase/) [25]. Reporters were excluded from
analysis if one of the following criteria were fulfilled: signal to noise ratio
< 3; standard deviation of the log2 transformed ratios between triplicates>
0.2; and only one informative replicate.
3 RESULTS
3.1 Clinical findings
The proband was referred to the genetic outpatient clinic at the age of 3
years because of psychomotor retardation. He was the oldest son of healthy,
non-consanguineous Caucasian parents. The pregnancy was unremarkable.
Because of advanced maternal age, an amniocentesis was performed which
revealed a normal male karyotype. He was born at 8 months gestation by
cesarean section because of solutio placentae. His birth weight was 2110 g
and length 42 cm. There were no signs of respiratory distress or asphyxia
after birth. However feeding problems were present due to poor suck reflex.
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Fig. 1. Facial features of the proband at the age of 10 years 9 months. Note
the downslanting palpebral fissures, broad nasal tip, everted lower lip and
prominent maxillary incisors
Later on, starting around the age of 6 months, chronic and recurrent upper
airway and gastrointestinal infections resulted in failure to thrive. His motor
development was delayed with sitting at the age of 10 months and walking
at the age of 22 months. Psychometric testing, performed at the age of 31
months, revealed a developmental age of 18 months (Bayley developmental
screening test). Neurological evaluation showed hypotonia with poor muscle
tone. Physical examination at the age of 34 months revealed a weight of 13
kg (-1.5 sd), length of 89,5 cm (-1.5 sd) and head circumference of 50,8 cm
(+1 sd). The head was relatively macrocephalic with a prominent occiput
and a flat forehead. His facial dysmorphism was characterized by small
palpebral fissures, bilateral epicanthal folds, small nares, broad nasal tip,
small but normally placed ears, small chin, high-arched palate and small
teeth. Other congenital anomalies were absent. His hands were relatively
small. CT scan of the brain, electroencephalogram, echocardiogram and
skeletal radiographs failed in revealing any abnormalities. On further follow-
up severe speech and language delay became apparent. At the age of 4 years
he started in special education school. His limited communication skills
and low self-esteem often resulted in frustration with aggressive behaviour
towards his parents, younger brother and other younger children. Last
evaluation was done at the age of 10 years 9 months. He still had a relatively
large skull (head circumference + 1sd) in comparison with weight (-2.5 sd)
and height (-2.2 sd). New clinical findings included downslanting palpebral
fissures, everted lower lip with drooling, prominent maxillary incisors, small
shoulders and thorax (figure 1).
3.2 Molecular cytogenetic findings
Chromosome analysis revealed a normal, male karyotype; 46,XY.
Subsequent array CGH analysis revealed a small interstitial deletion of
2 consecutive BAC-clones in chromosome band 18q12.3. The proximal
breakpoint was located between clones RP11-164M8 (37482575 bp) and
RP11-486C18 (40044271 bp). The distal breakpoint was situated between
RP11-463D17 (41408713 bp) and RP11-8H2 (41851567 bp) at the boundary
of band 18q21.1. This corresponded to an interstitial deletion of 1.4 to 4.4
Mb. The deletion was confirmed with FISH and breakpoints were further
Fig. 2. Overview of the deleted region, BAC colons used in FISH
analysis (green=not deleted, red=deleted, orange=breakpoint spanning), and
known genes in region. The karyotype can be written as 46,XY.arr cgh
18q12.3q12.3(RP11-486C18’RP11-463D17)x1
fine-mapped. The BAC clone RP11-187O19 (39888100 bp - 40067033
bp) encompassed the proximal breakpoint and the BAC clone RP11-431A4
(41528702 bp - 41701608 bp) the distal breakpoint. These findings reduced
the size of the deleted interval to a 1.8 Mb region (Figure 2). Karyotyping
and FISH analysis of both parents yielded normal results, indicating that the
deletion occurred de novo.
4 DISCUSSION
We present the first patient with a submicroscopic interstitial deletion in the
proximal part of the long arm of chromosome 18, del(18)(q12.3q12.3). The
deletion was detected by array CGH as part of a screen of 140 individuals
with mental retardation and multiple congenital anomalies (MR/MCA), as
reported elsewhere [2]. Several other patients have been described with
deletions encompassing band 18q12.3. Tinkle et al. has emphasized the
consistent pattern of phenotypic abnormalities observed in children with
the del(18)(q12.2q21.1) syndrome [20]. An overview of the phenotypical
characteristics of all previously described patients is provided by Kotzot et
al. [15]. Affected individuals have moderate to severe mental retardation
with only minor dysmorphic features. They are usually short and obese
and have relative macrocephaly with high forehead. Other reported facial
dysmorphic features include deep-set eyes with epicanthic folds, ptosis of
upper eyelids, strabismus, abnormal ears with prominent antihelices and
large lobules, hypoplastic midface with small nose and flat/wide nasal
bridge, wide/hypoplastic philtrum and a high arched palate [15,16,20]. The
dermatoglyphics in patients with del(18)(q12.2q21.1) are often reported to
be abnormal. Most patients present with hypotonia or seizures. Behavioural
problems such as autism spectrum disorder, hyperactivity and aggression
are not uncommon [26]. Interestingly, most of these features are present in
our patient who carries only a small deletion of 1.8 Mb in chromosomal
band 18q12.3, suggesting that the critical region for the del(18)(q12.2q21.1)
syndrome is residing in this part of chromosome 18. Krasikov et al.
postulated that the critical region for the interstitial 18q phenotype was
either located at q12.2 or q12.3 and does not require deletion of q21.1
[16]. Our findings confirm that only a small critical region on the long
arm of chromosome 18 is responsible for most, if not all, of the observed
features. According to the UCSC genome browser, this critical region
contains only 5 genes (SLC14A1, SLC14A2, SETBP1, CD33L3 and
KIAA1632). SLC14A1 codes for a urea transporter in human erythrocytes
and endothelial cells of the vasa recta of the kidney and is involved in
the KIDD (Jk) blood group system [27]. Although Jk-null red blood cells
have reduced urea permeability, the Jk deficiency is not associated with
2
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any obvious clinical phenotype except for a urine concentration defect [28].
SLC14A2 encodes a homologous urea transporter in the kidney [29]. Genetic
variation in the human urea transporter-2 is associated with variation in
blood pressure [30], whereas homozygous-null mice appear normal and are
fertile. However, after water restriction, the inner medullary tissue shows
a marked depletion in urea [31]. SET binding protein 1 (SETBP1) has
been described as a fusion gene with NUP98 (Nucleoporin, 98-KD) in
a case of paediatric acute T-cell lymphoblastic leukaemia with an 11;18
translocation [t(11;18)(p15;q12)] [32,33]. No further relevant functional
information was available for SETBP1, CD33L3 and KIAA1632. Besides
direct effects, gene expression can be perturbed by position effects due
to the separation of regulatory sequences from the core gene sequence.
As these position effects have been described for distances up to 900 kb
[34], information was collected on all genes in a 1 Mb interval flanking
the critical region. At least two other genes were selected because of
their potential involvement in the pathogenesis of the disorder observed
in our patient. RIT2 (RIC-like protein without CAAX motif 2), better
known as RIN (RAS-like protein expressed in neurons), belongs to the
RAS superfamily of small GTPases [35]. Small GTPases regulate a wide
variety of cell processes, including growth, cell differentiation and cell
movement. In contrast to other family members, RIT2 is only expressed
in neurons 35 and Rit2 induces neurite outgrowth in rat pheochromocytoma
PC12 cells [36]. In addition, Rit2 binds calmodulin in a Ca2+ dependent
manner, suggesting an important role in the calcium/calmodulin mediated
signalling pathways 35,36. Moreover, several other members of the RAS
superfamily of small GTPases have been shown to be implicated in mental
retardation syndromes. Mutations in HRAS have been described in patients
with Costello syndrome, loss-of-function mutations in KRAS are implicated
in Noonan syndrome and LEOPARD syndrome, while gain-of-function
mutations in KRAS have been described in cardiofaciocutaneous syndrome
37. The second candidate gene is SYT4 (synaptotagmin-4), a brain specific
member of a large family of synaptic vesicle proteins. Different hypotheses
have been postulated concerning its molecular function. Several studies
[38-40] ascribe a protective function to Syt4 upregulation in which neural
activity is reduced by inhibiting neurotransmitter release. However, others
postulate that Syt4 rather promotes than inhibits synaptic transmission [41].
Other functional evidence comes from the characterisation of Syt4 null
mice [42,43]. Learning and memory tests in these amorphic mice suggest
that Syt4 is critical for brain function and affects hippocampal-dependent
learning and memory. Furthermore, the mutant mice show impaired motor
coordination. Array CGH screening of patients with mental retardation and
similar phenotypic features could reveal more microdeletions in this region
and help us further in the confirmation and precise delineation of the critical
region on 18q12.3. This in turn might lead to the identification of the
responsible gene(s) for the del(18)(q12.2q21.1) phenotype.
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ABSTRACT
We report on a patient with mental retardation, seizures and
macrosomia with advanced bone age in whom a de novo apparently
balanced chromosomal rearrangement 46,XX,t(X;9)(q12;p13.3) was
identified. Using array CGH on flow-sorted derivative chromosomes
(array painting) and subsequent FISH and qPCR analysis, we
mapped and sequenced both breakpoints. The Xq12 breakpoint
was located within the gene encoding for oligophrenin 1 (OPHN1)
whereas the 9p13.3 breakpoint was assigned to a non coding
segment within a gene dense region. Disruption of OPHN1 by the
Xq12 breakpoint was considered the major cause of the abnormal
phenotype observed in the proband.
1 INTRODUCTION
A small subset of patients with mental retardation and/or congenital
abnormalities present with an apparently balanced de novo
chromosomal rearrangement. In most patients it is assumed that
the observed phenotypic anomalies are the result of submicroscopic
deletions or duplications or alternatively disruption, activation or
inactivation of a gene or genes located at or near the breakpoints.
Until now, only a limited number of such apparently balanced de
novo rearrangements have been investigated to the basepair level.
In some instances detailed analysis has led to the identification
of disease related genes [1]. Here we describe the combined
application of array painting [2], FISH and real-time quantitative
PCR which enabled us to map and sequence the breakpoints of a
balanced reciprocal translocation t(X;9)(q12;p13.3) in a girl with
mental retardation and overgrowth.
2 METHODS
2.1 G-Banding
Karyotyping was performed on short term lymphocyte cultures from
peripheral blood with G-banding. Karyotypes were described according to
the guidelines of the ISCN 2005.
2.2 Chromosome flowsorting
Purification of the translocated chromosomes, derivative 9 and X, was
carried out using a flow cytometer (MoFlo R©, DAKO) as described
∗to whom correspondence should be addressed
previously [2, 3]. DNA from the flow sorted chromosomes was used as
template for rolling-circle amplification (RCA) with Repli-G (Molecular
Staging). The amplified DNA was subsequently used as template DNA for
array painting,, qPCR and sequencing [2].
2.3 Array painting
Using random prime labeling, 500 ng of amplified derivative chromosome
9 and derivative chromosome X DNA was labeled with Cy3 and Cy5
respectively (BioPrime Array CGH Genomic Labeling System, Invitrogen).
Repetitive sequences were suppressed with 100µg Cot-1 DNA (Invitrogen)
and 400µg yeast tRNA. The labelled fragments were resuspended in 60
60µl hybridisation buffer at 37◦C (50% formamide, 10% dextran sulphate,
0.1% Tween 20, 2x SSC, 10 mM Tris pH 7.4). In-house produced 1Mb
BAC arrays were prehybridized at 37◦C during 1h using 50µg Cot-1
DNA (Invitrogen) and 150µg herring sperm DNA, resuspended in 120µg
hybridisation buffer. After removal of the prehybridization mixture, DNA
from both derivatives was simultaneously hybridized for 48h at 37◦C.
The slides were washed in 1x PBS/0.05% Tween 20 for 10 min at room
temperature, 50% formamide/2x SSC for 30 min at 42◦C and finally 1x
PBS/0.05% Tween 20 for 10 min at room temperature. After centrifuge
drying, the slides were scanned using a GMS 418 Array Scanner (MWG).
The scan images were processed with Imagene software (Biodiscovery) and
further analyzed with our in-house developed and freely available software
tool arrayCGHbase (http://medgen.ugent.be/arraycghbase/) [4]. Data points
were excluded from analysis if one of the following criteria were fulfilled:
signal to noise ratio < 5; standard deviation of the log2 transformed ratios
between triplicates > 0.2; only one informative replicate.
2.4 FISH with region specific probes
Fluorescence in situ hybridisation (FISH) was performed as described [5].
Locus specific RPCI-BAC probes for chromosome X and 9 were obtained
by screening several assemblies (http://genome.ucsc.edu/) of the human
genome project. All probes were relocated to the March 2006 Genome
assembly (Table 1). BAC probes were labeled either with digoxigenin or
biotin and hybridized on patients’ metaphase chromosomes.
2.5 Fiber-FISH
Fiber-FISH analysis was performed according to Speleman et al. [6]. Fiber-
FISH slides were prepared from a lymphoblastoid cell line of the patient
(EBV689) and a normal male control cell line (EBV99) and hybridized with
probes RP11-331F9, RP11-112J3 on chromosome 9 and probe RP3-360E18
on chromosome X, respectively flanking and spanning the breakpoint.
c© 2007. 1
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2.6 PCR analysis
Primers for qPCR were designed to amplify products along the sequence
interval of interest determined by fiber-FISH. qPCR was performed as
described previously [7]. Once the breakpoints were found to lie between
two primers, further primers were chosen to amplify fragments in between.
Junction fragments were generated by using forward and reverse primers
from the different chromosome sequences either side of the breakpoints.
2.7 Sequencing
The junction fragments were cleaned with exo-SAP (GE Healthcare)
sequenced by using the di-deoxy chain terminator method [8] with the
BigDye v3.1 ET terminator cycle sequencing kit from Applied Biosystems.
After the sequencing reactions, the products were electrophoresed on a
3100 Genetic Analyzer and analyzed with Sequence Analysis and SeqScape
(Applied Biosystems).
3 RESULTS
3.1 Clinical findings
The proband was born at 38 weeks gestation after an uncomplicated
pregnancy. Birth weight was 2580 g (P10), length 45,5 cm (P10=47cm) and
head circumference 33 cm (P10-P25). The postnatal course was uneventful.
The girl had a delayed neuromotor development with sitting at 11 months
and walking at 23 months. She developed a first epileptic insult at the age
of 10 months for which she was treated with phenobarbital. The seizures
were characterized by upward deviation of the eyes, anteflexion of the
head and flexion of the legs. A first evaluation at the age of 14.5 months
revealed a weight of 13.9 kg (P90=12kg), length of 82 cm (P90=81cm)
and head circumference of 47.5 cm (P50-P90). There was no clear facial
dysmorphism at that age. Just intermittent strabismus, a receding frontal
hairline and mild hypotelorism were noted. Diagnostic work-up because of
the seizures revealed a de novo balanced reciprocal translocation between
the long arm of the X chromosome and the short arm of chromosome 9
(46,XX,t(X;9)(q12;p13). An MRI of the brain showed only mild dilatation
of the ventricular system. Psychometric evaluation at the age of 18 months
revealed an IQ score of 60. Around the age of 3 years the antiepileptic
treatment was switched from phenobarbital to valproate. At the age of 5
years she started in special education school. On follow-up she developed an
accelerated growth with shift of all parameters at or above the 90th centile.
According to the bone age atlas of Greulich and Pyle, her bone age at the age
of 8 years was between 11 and 12 years. On the last physical examination she
was 8 years old. Weight was 69.4 kg (+4.6 sd) (BMI: 28.5), length 155.7 cm
(+1.38 sd) and head circumference 54.2 cm (+2 sd). She had a friendly and
affectionate personality. Her speech was not so easy to understand. When
talking, she tended to hold her head in an oblique position, thus looking
mainly with the left eye. Dysmorphic facial features included prominent
incisors and relatively large ears (figure 1).
On the trunk a supernumerary nipple on both sides was observed. A mild
extension deficit was present in the elbows and knees. In the upright position,
she was holding her knees in mild flexion. Her gait was slow and unsteady.
Her feet were small and flat.
3.2 Molecular cytogenetic findings
Partial G-banded karyotypes of the apparently balanced chromosomal
rearrangement are shown in figure 2A. The karyotype could be described
as 46,XX,t(X;9)(q12;p13). Following chromosome sorting and rolling circle
amplification, array painting was performed (Figure 2B). Together with
FISH analysis using region specific probes (Table 1), the breakpoint could
be localized in BAC RP11-360E18 on chromosome Xq12 and in between
BACs RP11-331F9 and RP11-112J3 on chromosome 9p13.3 (Figure 2B).
The breakpoints were fine mapped using fiber FISH and could be further
localised in RP11-360E18 and RP11-331F9 to an accuracy of ˜20kb (Figure
Fig. 1. Clinical photograph of the proband at the age of 8 years showing
obesity and mild facial dysmorphism with prominent maxillary incisors,
relatively large ears and high forehead.
Fig. 2. Derivative chromosome 9 and derivative chromosome X after G-
banding (A) array CGH profile after array painting for chromosome X and
chromosome 9 (B) Fiber-FISH results with BAC clones RP11-112J3, RP11-
360E18 (red) and BAC clones RP11-331F9 and RP11-112J3 (green) (C)
2C).
Consecutive qPCRs allowed us to narrow down the breakpoint on
chromosome X between 67404215 bp and 67407331 bp (3116 bp)
and on chromosome 9 between 35656338 bp and 35656776 bp (438
bp). Subsequently, using appropriate primers on both derivatives, both
breakpoints were amplified and sequenced. (Figure 3).
4 DISCUSSION
We report on a girl with mental retardation (IQ=60) ,seizures and
macrosomia with advanced bone age. Congenital abnormalities of the
internal organs were not observed. Only a mild craniofacial dysmorphism
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Fig. 3. Sequence of both breakpoints. A for derivative 9 and B for derivative
X. The nucleotides in bold represent chromosome 9 sequence, the underlined
nucleotides represent primer sequence used for cloning, the adenine between
brackets indicates one basepair which is lost either from chromosome 9 or
chromosome X.
Fig. 4. Genomic context of the breakpoints on chromosome 9 (A) en
chromosome X (B) with the RefSeq genes (UCSC Genome Browser on
March 2006 Assembly) in a 500kb interval upstream and downstream of
the breakpoint. The dotted line indicates the breakpoint
with strabismus and a receding frontal hairline was noted. On the trunk,
a supernumerary nipple on both sides was present. Brain MRI revealed
a mild dilatation of the ventricular system. Karyotyping was performed
and revealed an apparently balanced translocation: 46,XX,t(X;9)(q12;p13).
Breakpoints were sequenced after flow-sorting and array painting in order
to determine their genomic position. On Xq12, the breakpoint interrupts
the 390kb large oligophrenin 1 gene (OPHN1) (Figure 4). OPHN1 has
25 exons and encodes a Rho-GTPase-activating protein. The Rho proteins
are important mediators of intracellular signal transduction affecting cell
migration, cell morphogenesis and synapse maturation [9]. The oligophrenin
protein regulates cytoskeletal dynamics through Rho-GTPase modulation
and is specifically involved in dendritic spine morphogenesis [10]. Of all
the genes involved in X-linked mental retardation, six encode regulators
or effectors of Rho-GTPase proteins, suggesting an important role of
the Rho signalling pathway in cognitive functions [11]. Oligophrenin
expression is highest in the developing central nervous system, and more
precisely in the neuronal and glial cells [12]. In adult life, oligophrenin
expression is enriched in the hippocampus, the olfactory bulb, and the
Purkinje cell layer of the cerebellum. Although OPHN1 mutations were
first described to cause a rather nonspecific form of mental retardation
[9], several publications have now highlighted the recognizable phenotype
with neurological abnormalities and mild facial dysmorphism [11, 13, 14].
Cerebellar hypoplasia with vermian dysplasia is frequently observed on
brain imaging studies and seem to result in dysmetria, adiadochokinesia, and
oculomotor problems (nystagmus, strabismus, external ophthalmoplegia) in
the affected individuals. [15, 16]. Ataxia is rarely observed. Seizures are
commonly reported. The expression of oligophrenin 1 in the craniofacial
skeleton, especially at the level of the mandible [11] may explain the
facial dysmorphism seen in some patients with the ‘oligophrenin syndrome‘.
The craniofacial dysmorphism is more pronounced in older patients and
includes a long face with prominent chin, hypotelorism, deep-set eyes
with prominent supraorbital ridges, long tubular nose, short philtrum, and
thin upper lip. Macrocephaly and tall stature have also been reported
in several families [11, 17], In accordance with its X-linked recessive
inheritance pattern, the ‘oligophrenin 1 syndrome‘ phenotype is usually
encountered in affected males, with female carriers only showing a rather
mild and nonspecific phenotype (learning difficulties and strabismus) unless
they carry an X;autosome translocation as is illustrated by our patient. In
females with an X;autosome translocation, X inactivation initially occurs
at random but is followed by cellular selection, favouring the cells without
a partial autosome inactivation. Accordingly, nearly 95% of females with
a balanced X;autosome translocation show a skewed X-inactivation pattern
with the normal X chromosome inactivated in almost all cells [18]. This
explains the more pronounced phenotype observed in females with an
X;autosome translocation. The chromosome 9p13 breakpoint is localised
within a noncoding segment on chromosome 9. A position effect on the
expression of the flanking genes can not be ruled out. Position effects due
to chromosomal aberrations, leading to altered expression of genes have
been described up to 1.3 Mb of the breakpoint [19, 20]. This possibility was
not further investigated because the major part of the abnormal phenotype
in our patient could be explained by the disruption of the OPHN1 gene.
So far, only a few constitutional, apparently balanced, translocations have
been mapped at the sequence level, mostly due to the huge amount of
experimental laboratory. However, the information on responsible genes
obtained through above described efforts is of the utmost importance. In
fact, the OPHN1 gene was identified through the breakpoint analysis of a
female patient with a t(X;12) translocation [21]. The strategy followed in this
study is an example of a clear cut way to facilitate the analysis of balanced
translocations, enabling to narrow down the translocation breakpoints in
only a limited number of experiments. Although technically challenging,
this study further illustrates the feasibility for rapid breakpoint mapping and
sequencing, using a combined approach of chromosome flow sorting (or
alternatively microdissection), linear DNA amplification and array CGH.
It can be anticipated that similar studies on larger series of de novo
apparently balanced translocations in mentally retarded patients will lead
to the discovery of several new genes as a cause for mental retardation.
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Abstract
Background: The availability of the human genome sequence as well as the large number of
physically accessible oligonucleotides, cDNA, and BAC clones across the entire genome has
triggered and accelerated the use of several platforms for analysis of DNA copy number changes,
amongst others microarray comparative genomic hybridization (arrayCGH). One of the challenges
inherent to this new technology is the management and analysis of large numbers of data points
generated in each individual experiment.
Results: We have developed arrayCGHbase, a comprehensive analysis platform for arrayCGH
experiments consisting of a MIAME (Minimal Information About a Microarray Experiment)
supportive database using MySQL underlying a data mining web tool, to store, analyze, interpret,
compare, and visualize arrayCGH results in a uniform and user-friendly format. Following its
flexible design, arrayCGHbase is compatible with all existing and forthcoming arrayCGH platforms.
Data can be exported in a multitude of formats, including BED files to map copy number
information on the genome using the Ensembl or UCSC genome browser.
Conclusion: ArrayCGHbase is a web based and platform independent arrayCGH data analysis tool,
that allows users to access the analysis suite through the internet or a local intranet after
installation on a private server. ArrayCGHbase is available at http://medgen.ugent.be/arrayCGHbase/
.
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Background
The introduction of a microarray based comparative
genomic hybridization method (arrayCGH) in 1997
paved the way for higher resolution detection of DNA
copy number aberrations [1]. ArrayCGH is founded on
the same principles as metaphase CGH, but uses mapped
reporters instead of whole chromosomes. One of the
major challenges in arrayCGH studies remains the acces-
sibility, management, and interpretation of the vast
amount of data generated in single experiments, and par-
allel comparison of multiple experiments. Typically, these
arrays contain 3,000 to 30,000 reporters, each of which
has multiple biological annotations (chromosomal posi-
tion, sequence information, gene name, biological and
molecular function,...) as well as physical (grid layout)
and quality control (sequence verification, FISH mapping
information,...) annotations. In addition, the description
of the DNA samples under investigation and the applied
lab protocols should be easily accessible. For classical
CGH, several commercial software packages are available
to analyze and interpret the data of a CGH experiment.
Also for arrayCGH there are a number of separate software
systems that individually address some of the needs, such
as databases for data storage (BASE [2]), applications for
clustering and visualization of microarray data (seeGH
[3], M-CGH [4], CGHAnalyzer [5], aCGH-smooth [6] and
CGH-Miner [7]), public genome databases that contain
reporter information, commercially available Laboratory
Information Management Systems (LIMS), and various
storage methods for recording biomaterial annotations.
However, none of these software packages or databases
combine all these features (see Supplemental Table). In
this paper, we present the development of a web based
open source arrayCGH analysis platform, arrayCGHbase,
that combines all these features and on top provides addi-
tional unique aspects making the analysis and sharing of
arrayCGH data easily implementable for both research
and routine purposes.
Implementation
MIAME compliant database
arrayCGHbase runs in Windows, Linux, Macintosh, and
Unix environments. Particular attention was paid to the
use of open source software for the development of array-
CGHbase. The software was developed in the PHP script-
ing language, with all data being stored in a relational,
MIAME [8] (Minimal Information About a Microarray
Experiment) supportive, MySQL database and communi-
cated to the user through an Apache Web server (Figure 1).
After installation on a private server, experiments can be
shared by different users over the internet or a local
intranet. ArrayCGHbase integrates DNA sample informa-
tion, lab protocols, extracted data, and contains a plug-in
architecture for data transformation, analysis, and graphi-
cal display, allowing users to develop their own modules.
Reporters can be directly linked to the Ensembl [9] or
UCSC [10] genome browsers, providing additional up-to-
date information on each reporter. Reporters can also be
manually imported into the MySQL database with the
ability to update all linked experiments. The structure of
arrayCGHbase was designed to follow the laboratory
workflow and is compatible with all types of arrayCGH
experiments and data formats (dual colour genomic
clone, cDNA [11], or oligonucleotide [12] arrays spotted
on any substrate, physical layout, type of array, as well as
single channel hybridizations such as the Affymetrix SNP
chips [13]). With a personal account and administrated
access levels, a user can enter new DNA samples, annotate
these, and append all relevant sample information such as
quantity, quality, and applied lab protocols at each step.
Each user can group experiments together into projects
and, in a uniform and streamlined fashion, apply filters
and transformations and run analyses. Data is exportable
in several formats for offline analysis using other (dedi-
cated) software tools, for publication or for sharing data
with the research community. For advanced users, an SQL
query window allows interrogation of the underlying
MySQL database.
Data processing and visualization routines
A first and important step in data analysis of arrayCGH
experiments is the processing of large, possibly noisy data
sets to identify the specific reporters that are differentially
hybridized and hence show an aberrant copy number.
Data processing is performed in a streamlined four-step
manner: (1) the local noise or background associated with
the experiments is removed, (2) the quality of the experi-
ment is assessed and poor quality features are removed,
(3) ratios are calculated, transformed to log2 scaled ratios,
and normalized, and finally (4) reporters that show
altered ratios are identified and hence, reporters with
aberrant copy number are identified. In the past, this nor-
mally required the sequential processing of data by differ-
ent, often incompatible programs. Using established and
widely used microarray (CGH) data processing proce-
dures, arrayCGHbase will automatically correct the signal
intensities, filter out unwanted poor quality features
(based on signal to noise ratio, image processing software
related flags, or other user defined filters), normalize the
fluorescence intensity ratios, score levels of differential
hybridization, combine the results of replicate experi-
ments and assess the quality of individual and replicate
experiments. All these steps are user adjustable.
Input data and local background correction
The experimental input data for arrayCGHbase consists of
export files generated by image analysis software. Cur-
rently, the program recognizes files from GenePix Pro ver-
sions 2.0–4.0, Scanalyze version 2.0, UCSF SPOT version
2.0, Imagene versions 4.0 – 5.5 and the Affymetrix
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arrayCGHbase schemeFigure 1
arrayCGHbase scheme. The data is stored in a MIAME supportive MySQL database (red) and reporter info is updated using 
the NCBI, Ensembl and UCSC genome database. Data and results are presented to the user through a web browser via the 
PHP scripting language. Data-normalization and other analysis or result visualization methods can be integrated using the plug-
in architecture. Further data processing using the R statistical scripting language will be implemented in the near future. Results 
can be exported to a Progenetix or MIAME compatible format, or visualized on the genome using the Ensemble or UCSC 
genome browser.
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Chromosome Copy Number Tool. The program can easily
be updated for the recognition of other data input formats
upon request. Moreover, arrayCGHbase has an interactive
import wizard, which makes it possible to import data at
your own desire. The processing steps may be changed by
altering the parameters at the input stage. By default, the
results for each feature are defined as the median fore-
ground minus background intensities for each dye (as
determined by the image processing software). The ratio
of each feature is determined as the relative background
corrected signal between the two dyes or in the case of sin-
gle color experiments as the corrected signal intensity.
Poor quality flagging
Nearly every experiment contains features of poor quality,
comprising features that have unusual morphology (e.g.
doughnut patterns), exhibit uneven hybridization, or
have saturated signal intensity. After background correc-
tions, arrayCGHbase can automatically flag features of
inferior quality using different criterions (e.g., the stand-
ard deviation between replicates), by a manually set signal
or signal-to-noise threshold, or using image processing
generated flag annotations.
Normalization
Following calculation of the corrected signal intensities
and filtering for good quality features, the relative contri-
butions of the fluorescence intensities are compared. To
go from a multiplicative space to an additive space, ratios
are log2 transformed. Ideally, the signals of the two dyes
should be equal for nucleic acid reporters that have equal
amounts in the test and reference samples (i.e., the log2
transformed ratios of the two corrected signals should
approach zero for reporters hybridizing to an equal degree
in both fluorescence channels). However, in practice the
ratio of the corrected signal intensities deviates from the
expected ratio due to the different molecular and physical
characteristics of the dyes, the different amounts of DNA
used for labeling with the different dyes, the spatial heter-
ogeneity in the hybridization conditions across the slide,
and many other factors. Normalization compensates
these effects by applying a data transformation such that
ratios of reporters with unchanged copy-number are close
to zero. In the normalization step, an appropriate term is
added or subtracted from the log2 transformed ratio for
each feature. The program allows normalization in several
ways, either by global normalization or subgrid (or pin)
normalization, or by a combination of different normali-
zation procedures.
A major issue in microarray normalization is the defini-
tion of the set of constant probes to which the data are
normalized. The most widely accepted method employs
the 'constant majority' method, which assumes that the
majority of reporters do not change in ratio. This method,
which is implemented in arrayCGHbase, is generally appli-
cable to most experiments as it is valid even in cases where
up to 50% of reporters have altered ratios, it does not
require prior knowledge of which features remain con-
stant, and allows for intensity and spatial variation.
Hence, this method calculates a scaling term from the
median of all ratios, excluding all outliers. In this way the
distribution of all ratios is transformed so that it centers
around zero.
Quality control
Percentage of good quality spots
This first quality assessment is a basic calculation of the
number of reporters (or features) that are not flagged
based on quality measures (user defined parameters and
thresholds, see above).
Intra- and inter-array hybridization quality
Three other major quality parameters can be determined
with arrayCGHbase for each experiment. The first assesses
the variation between reporters present in replicates on
the array (typically duplicates or triplicates). An increased
variation typically reflects lower quality hybridizations
resulting in less reliable ratios. A second quality parameter
is the standard variation between the different reporters
on the array that show a normal (unaltered) copy
number. This quality measure is only applicable in exper-
iments with few reporters with aberrant copy number. The
third quality measure is the average ratio for reporters
with aberrant copy number. This ratio should signifi-
cantly differ from zero to allow identification of differen-
tially hybridized reporters. This last quality measure is
only applicable in experiments where DNA copy number
aberrations are known or validated. These parameters pro-
vide an objective quality measure and can also be helpful
to compare different experiments.
In addition to these parameters, different graphical dis-
plays, such as ratio-intensity plots (usually referred to as
MA plots), dual channel intensity scatter plots, and ratio
histograms give an idea of the quality of an individual
experiment or series of experiments (Figure 2). In all these
visualizations, thresholds for gains and losses are dis-
played and can be adjusted. The slide viewer generates a
virtual spatial view of all features on the array using the
ratio, or signal and background intensities; this viewer
allows the identification of problematic regions or arti-
facts on the slide surface. Clicking on an individual feature
shows specific data associated with this feature (e.g.,
reporter name, signal intensities, and data quality flags).
Scoring chromosomal regions with aberrant copy number
The final step in arrayCGH data processing is the identifi-
cation of reporters that exhibit differential hybridization,
corresponding to chromosomal regions that have altered
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Quality control graphsFigure 2
Quality control graphs. Graphical displays to assess the quality of an experiment, such as a dual channel intensity scatter 
plot, ratio histogram, ratio-intensity plot and a virtual slide view.
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copy number. The major issue is to identify those report-
ers whose relative ratios stand out from the experimental
noise with sufficient statistical significance. arrayCGHbase
currently incorporates two scoring methods. The most
widely used approach is to define a ratio threshold and
identify the probes that exhibit ratios greater or smaller
than this threshold. Another, statistically more sound
approach, is to use a floating threshold based on the
standard deviation of all reporters in a given experiment.
Reporters that exhibit ratios greater than this threshold
will be defined as differential [14]. Both methods are
implemented in arrayCGHbase and can be applied on
each individual feature, or on the mean value of repli-
cates. Besides the aberrant feature scoring methods, two
other algorithms are available: a universal data smoothing
algorithm, as well as a breakpoint-identification algo-
rithm, which both consist of a moving window along the
chromosomes and hence make use of the spatial "along
the chromosome" distribution of the reporters. With
these algorithms, chromosomal breakpoints can be easily
identified in more noisy datasets. By writing custom plug-
ins (in PHP or R), sophisticated algorithms that use seg-
mentation methods (e.g. Cluster Along Chromosomes,
CLAC [7]) or others, can be implemented by any user in a
straightforward way.
Chromosome visualization
A wide variety of result viewers are available. The results
can be mapped upon standard ISCN (International Stand-
ard on Cytogenetic Nomenclature) ideograms in an elec-
tronic karyotype, or visualized per chromosome or
zoomed in on a region of interest (Figure 3). Moreover,
various CGH profile views provide the user with a tool to
compare different experiments and to identify regions
with relevant copy number alterations. Views are returned
to the user either as PNG (Portable Network Graphic) or
as SVG (Scalable Vector Graphic) files, with the ability to
scale images according to screen width.
Data export
Processed data can be exported as MIAME compliant text
files and figures; these include the original feature signal
and background intensities, the normalized ratio value, a
list of reporters that are differentially hybridized, and the
data quality parameters. Additionally, a file can be gener-
ated for submission of arrayCGH results directly into Pro-
genetix [15], a comprehensive collection of published
cytogenetic abnormalities in human neoplasms. Lastly,
BED files can be created to map results and visualize the
experiment from within the Ensembl or UCSC genome
browser.
ArrayCGHbase at work
In several publications from our research group, array-
CGHbase has been successfully used to analyse arrayCGH
data to identify and delineate copy number aberrations
[16-19]).
At the demo site, users can explore the data published in
Hellemans et al. [16], a small ~5 Mb deletion in chromo-
some 12q identified using SNP chips), the results of a case
report of the identification of an unbalanced X-autosome
translocation by arrayCGH in a boy with a syndromic
form of chondrodysplasia punctata brachytelephalangic
type [17], a distal 9p trisomy and distal Xp nullisomy
caused by an unbalanced X;9 translocation: 46, Y,
der(X)t(X;9)(p22.32;p23) detected with a 1 Mb BAC
array), and the copy number profile of a cancer cell line
NGP.1A.TR [18]). It is possible to look at the raw data of
these hybridizations and more importantly, test the per-
formance of the program using different settings.
Conclusion
We present arrayCGHbase, a versatile web based, platform
independent data storage and analysis tool for processing
microarray CGH data. Routines were implemented for
feature flagging, data normalization, data quality assess-
ment and the identification of chromosomal regions with
aberrant copy number. A zoomable graphical interface
allows immediate identification of altered genomic
regions and the underlying gene content by several
database links. A multitude of export functions allow the
user to further process the results. The easy plug-in archi-
tecture makes it possible for each user to add custom algo-
rithms for data analysis and visualization and share these
with the user community. This webtool and database will
enable investigators to interpret single experiments and
compare large data sets efficiently throughout different
array platforms and provides all of the essential features
and links for further investigation of the genomic regions
of interest.
Future developments
arrayCGHbase will continually be updated to incorporate
new processing methods that will be developed both
within and outside our laboratory. Immediate plans
include the addition of export and import functions to R
[20] or Bioconductor [21] to be able to apply several avail-
able mathematical algorithms such as two-dimensional
LOWESS normalization [22]. Immediate export functions
to the DECIPHER web site [23] to link phenotypical data
to actual experiments will also be included. The array-
CGHbase source code is freely available under a Creative
Commons License, to encourage others to develop new
analysis methods and utilities that will further improve its
capabilities.
Availability and requirements
An arrayCGHbase demo site is available at http://
medgen.ugent.be/arrayCGHbase/. At this site, all quality
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Selected result viewersFigur  3
Selected result viewers. Graphical displays of arrayCGH results of neuroblastoma cell line NGP.1A.TR1: line view (all 
reporters ordered by chromosome and chromosomal position on one line), karyo view (al reporters mapped on their chro-
mosomal position on a standard ISCN ideogram), chromosome view (zoom on one chromosome or chromosomal region) 
with breakpoint identification algorithm, and genome browser view (neuroblastoma cell line IMR32), with all reporters and 
their copy number status displayed in the UCSC genome browser.
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control features and other features can be tested for several
experiments with BAC arrays as well as SNP chips (see
'arrayCGHbase at work'). At the same site, the complete
package can be freely downloaded for local installation on
a private hosted web server. For local use, additional soft-
ware is required such as the MySQL database [24], a web
server (e.g. Apache [25]), and PHP hypertext preprocessor
[26]. These software packages are freely available and are
key parts of LAMP (Linux, Apache, MySQL, PHP), an open
source web platform. Enquiries for arrayCGHbase should
be made to arrayCGHbase@medgen.ugent.be.
Glossary
Reporter: any DNA fragment (BAC, PAC, cosmid, fosmid,
cDNA clone, oligonucleotide, genomic PCR product)
used for hybridization
Feature: physical reporter spotted, printed, or otherwise
linked to a substrate at a specific location
PHP: Hypertext PreProcessor (server-side scripting
language)
MIAME: Minimal Information About a Microarray
Experiment
MySQL: My Structured Query Language
ISCN: International System for human Cytogenetic
Nomenclature
BED: Browser Extendable Data
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chapter 4
General Discussion and Future Perspectives
This thesis is part of a wave of new findings
emerging from array CGH investigations that
herald a new era in cytogenetics. After the suc-
cessful implementation of array CGH in our lab,
a large cohort of ˜200 well selected patients with
mental retardation and/or congenital abnormal-
ities (MR/CA) was screened for submicroscopic
aberrations. The present work highlights a num-
ber of important aspects of array CGH investi-
gations in the study of mental retardation and
congenital abnormalities (MR/CA).
The Implementation of High Resolution DNA
Copy Number Analysis in the Investigation of
Patients with Mental Retardation and/or Con-
genital Abnormalities
In a close collaboration with The Center for Hu-
man Genetics, Leuven, Belgium and The Well-
come Trust Sanger Institute, Hinxton, Cam-
bridge, UK, a large insert clone array to cover
the entire genome with an average 1 Mb res-
olution was developed. Protocols were opti-
mized and quality criteria were defined and re-
ported [60, 61]. Screening for submicroscopic
aberrations in patients with a normal karyotype,
and mental retardation and/or congenital ab-
normalities resulted in the identification of an
unbalanced t(X;9) translocation in a boy with
the brachytelephalangic type of chondrodyspla-
sia punctata, mental retardation and obesity
[187]. The identification of this de novo chro-
mosomal rearrangement not only made accurate
genetic counseling possible but also explained
most of the phenotypic abnormalities observed
in this patient. This paper nicely illustrated the
new possibilities offered for sensitive screening
of submicroscopic chromosomal imbalances by
array CGH.
The Incidence of Copy Number Variations in
Patients with MR/CA
This and other pioneering array CGH analyses
[83, 188–192] on a total of 432 investigated pa-
tients with idiopathic mental retardation and/or
congenital abnormalities (MR/CA) showed that
in about 20% of cases chromosomal imbalances
(DNA copy number variations, CNVs) were de-
tected. This clearly reflects the high resolution
of array CGH, which can detect CNVs of 1 Mb
or less depending on the density of reporters
spotted on the arrays, in contrast to standard
karyotyping which has a resolution limited to
5-10 Mb. CNVs detected with array CGH in-
clude deletions, duplications and in some in-
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Figure 4.1 – overview of all chromosomal imbalances detected with array CGH in patients with mental
retardation and multiple congenital abnormalities (MR/MCA). In some of these patients a chromosomal
aberration was detected with conventional karyotyping, but array CGH was used to unambiguously identify
and delineate the genomic defect.
stances cryptic unbalanced translocations. Our
study and review of literature data allowed for
the first time to obtain a reliable assessment of
the incidence of de novo CNVs occurring in this
patient group, a figure which was determined to
be in the range of ˜8% (excluding patients with
subtelomeric imbalances).
Genomic Distribution of Chromosomal Aberra-
tions in MR/CA Patients and Genomic Causes
for Chromosomal Rearrangements
A second important observation which we could
make based upon our array CGH screening and
review of available data was the fact that most
of the CNVs seem to be scattered through-
out the entire genome. Figure 4.1 gives an
overview of all chromosomal imbalances in pa-
tients with mental retardation and multiple con-
genital abnormalities detected with array CGH
in our center. In contrast to most of the re-
current deletion/duplication syndromes, for the
great majority of the newly identified CNVs no
direct evidence was found for an underlying role
of the genomic structure in the formation of
these CNVs. Although further high resolution
mapping of many of these breakpoints is still
ongoing, there is no evidence for the implica-
tion of segmental duplications (also termed Low
Copy Repeats, LCRs) through non allelic ho-
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mologous recombination. One of the exceptions
in this regard is the newly discovered recurrent
microdeletion syndrome mediated by LCRs on
chromosomal band 17q21.31 [149–151]. Nev-
ertheless, for some chromosomal regions evi-
dence is accumulating that some form of ge-
nomic instability (or other mechanism) seems
to be implicated. One series of examples are
the frequently occurring 1p36 deletions which
occur with an incidence of 1/5000 - 1/10000
and which seem to target a whole range of dif-
ferent breakpoints located within chromosomal
band 1p36 [162, 164]. In our patient cohort we
also identified in two patients an interstitial 1p36
deletion with distinct breakpoints for each of the
two cases, further corroborating previous data.
The Long Way Towards the Description of the
Human Morbid Map and Functional Annotation
of the Human Genome
Determining the genotype/phenotype relation-
ship in contiguous gene syndromes is a critical
step in localizing the genes involved in the dif-
ferent characteristics of the phenotype and in
understanding the underlying molecular basis of
the different aspects of the condition. The ma-
jor challenge in defining new microdeletion syn-
dromes is to collect patients with overlapping
deletions (or duplications) and to try to delin-
eate common clinical features. An important
milestone of this work has been the description
of a new microdeletion syndrome on chromo-
some band 12q14 [165]. In the case of the
12q14 deletion the collection of additional pa-
tients was facilitated through the presence of a
very peculiar clinical feature, i.e. osteopoikilo-
sis. For many patients with a given CNV such a
characteristic feature may not be present which
may hamper or slow down collection of similar
patients. As indicated in the Introduction sec-
tion several initiatives have been taken in order
to coordinate the daunting task of collecting all
these data (Decipher, Ecaruca). This approach
has been proven to be productive as illustrated
by e.g. the detection of the new 17q21.31 dele-
tion syndrome.
Another important aspect of the ongoing array
CGH screening of MR/CA patients is the col-
lection of patients which may allow further re-
fined clinical description of the various CNVs.
Systematic screening will allow the description
of some of the known microdeletion syndromes
in children at younger age than the age when
patients are more typically referred. Also, some
of the more rare deletion/duplication syndromes
will now be described in much greater detail as
an increasing number of patients is being de-
tected. As an illustration, in our study we identi-
fied a patient with the reciprocal of the 7q11.23
deletion (ie the duplication) in Williams-Beuren
syndrome. Because the girl is still very young, it
is hard to compare her phenotypical characteris-
tics with the recently published cases of 7q11.23
duplications [159], but as indicated, such clinical
information is important as part of the emerg-
ing syndrome description. The finding of CNVs
in relation to clinical disorders also opens, as
mentioned previously, the possibility for identi-
fying genes that contribute to specific aspects of
the phenotype and are integral part of the func-
tional annotation of the human genome. To-
gether with the clinical relevant information ar-
ray CGH has provided, another currently less de-
fined ‘product‘ of array CGH analyses has come
to the surface, the so called normal copy number
variation.
Normal Copy Number Variation
The study of the human genome of normal in-
dividuals using high resolution array CGH has
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unveiled a new level of large scale copy num-
ber polymorphisms, i.e. segmental duplications
or Low Copy Repeats (LCRs) [108–110]. A
number of studies using different methodolo-
gies have uncovered this important source of
normal variation [193, 194]. More recently, an
in depth study was conducted using both BAC
and SNP arrays, providing a detailed inventory
of this new type of variation in the human [106].
A stunning total of 1447 copy number variable
regions (CNVRs), covering 360 Mb and encom-
passing 12% of the entire human genome, were
identified. These CNVRs represent more nu-
cleotides than SNPs identified thus far, under-
scoring the importance of CNV in genetic diver-
sity and evolution [106]. When applying array
CGH in the study of patients’ genomes this nor-
mal variation may complicate straightforward
interpretation of deletions or duplications, in
particular for chromosomal regions for which
genotype-phenotype correlations have not been
thoroughly studied. Typically, such CNVs are
assumed to be causal when not present in both
parents. When one of the parents also carries
the CNV, its relation to the patients’ phenotype
becomes more difficult to interpret. To facilitate
the interpretation of such CNVs, a database has
been established which collects all data on such
CNVs (http://projects.tcag.ca/variation/). If
CNVs have been not been reported before, the
clinical geneticist will not be able to make firm
conclusions, and even when such CNVs have
been reported as variants, care should be taken
in interpreting the data. Hemizygosity of genes
due to chromosomal deletions will not always
lead to haploinsufficiency, but a deletion may
unravel a nonsense mutation on the remaining
allele resulting in an affected child with an in-
herited deletion from one parent and a reces-
sive mutation from the other parent [195]. In
addition, epigenetic factors can have an effect
through aberrant methylation etc. [180, 185].
Moreover, it is known that some microdele-
tion syndromes (and other genetic diseases) can
show a variable phenotypic spectrum and pen-
etrance, ranging from normal to severely af-
fected, as exemplified by the 22q11.2 deletion
syndrome [152].
Identification of Genes Leading to MR/MCA
In the past, chromosomal aberrations have been
very helpful in the identification of disease genes
and genes involved in particular malformations
when perturbed. Such examples are the TBX1
gene within the 22q11.2 deletion interval impli-
cated in the characteristic aortic arch malfor-
mations, the EXT1 and TRPS1 gene leading
to the pathognomonic skeletal features of the
Langer-Giedion syndrome and the elastin gene
(ELN) in Williams-Beuren syndrome [19]. In
some instances, the genes leading to mental re-
tardation have been unmasked from the rela-
tively large series of genes for which hemizygos-
ity results from the recurrent deletion, e.g. the
lissencephaly gene (LIS1) in Miller-Dieker syn-
drome [144] and the RAI gene in Smith-Magenis
syndrome [196]. However, in most instances,
the genes contributing to the specific phenotypic
components of the deletion syndromes are diffi-
cult to identify. For the recurrent deletion syn-
dromes this is due to the fact that breakpoints
are almost always at the same locus and the rela-
tively large number of genes implicated. For non
recurrent deletions (or duplications) genotype-
phenotype correlation is hampered by the lack
of patient series which allow to assess the pheno-
typic variability. Despite this limitations, array
CGH has also contributed to the identification
of new disease genes. The gene responsible for
CHARGE syndrome was identified by screening
several patients with this condition and identi-
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fying two patients with a 2.7 Mb de novo over-
lapping microdeletion on 8q12. A subsequent
candidate gene approach - sequencing the can-
didate genes in the deleted interval in patients
with CHARGE syndrome without a microdele-
tion - lead to the identification of CHD7 (chro-
modomain helicase DNA-binding protein 7) as
the causal gene [129]. As illustrated by the
present thesis, high resolution array CGH analy-
sis of a 12q14.3 deletion has helped in the identi-
fication of LEMD3 as the causal gene for osteo-
poikilosis, Buschke-Ollendorff syndrome (BOS)
and melorheostosis by diminishing a candidate
region identified by linkage analysis [197].
Array CGH analysis of apparently balanced chro-
mosomal translocations, detected a high fre-
quency of cryptic deletions and duplications at
the breakpoints [198]. Although array CGH can-
not provide information on truly balanced struc-
tural rearrangements, the combination of flow
cytometry of derivative chromosomes and array
CGH (array painting) has led to the character-
ization of these breakpoints [199, 200]. This
technique helped us in the identification of
oligophrenin 1 (OPHN1) as the causal gene
for the observed mental retardation and over-
growth in a patient with a t(X;9) transloca-
tion [166]. The present work also illustrates
the possible contribution of array CGH in the
delineation of the critical region for recurrent
deletion syndromes. In this study we identi-
fied a small interstitial deletion on chromosome
18q12.3 in a patient with clinical features of the
del(18)(q12.1q21.1) syndrome. We were able
to delineate the critical region for this syndrome
to an interval of 1.8 Mb, enabling hereby the
determination of the crucial genes for this mi-
crodeletion syndrome [201].
Although currently there is no cure for mental
retardation, a recent study on the Down syn-
drome mouse model has indicated that attenu-
ating the severity of mental retardation is not
so unrealistic as it may seem at first sight [202].
Identifying the underlying causal genes and their
function, may help in the development of a
proper treatment in patients with mental retar-
dation.
Array CGH: Reflections Regarding Future Ap-
plications and the Relation versus Classical
Cytogenetics
From the results of this thesis and concurrent
studies performed worldwide it cannot be ig-
nored that array CGH is most likely to be-
come the method of choice for the search for
genome wide deletions and duplications in the
human genome. At present, karyotyping re-
quires in most instances the culture of living cells
and the skill full preparation and interpretation
of banded chromosomes. This requires highly
trained technicians and implicates a time con-
suming procedure. Array CGH will become a
standard molecular technique. DNA isolation,
simple DNA labeling using commercial kits and
well controlled denaturation and subsequent hy-
bridization, are steps amenable for automation,
which can be performed within less than 2 days.
Data handling is facilitated through dedicated
software and interpretation of (technical) results
is simple and straightforward, as specifically il-
lustrated in this thesis by the development of our
own dedicated web based software tool array-
CGHbase [203]. Although prices for slides and
consumables are at present still relatively high,
the above mentioned advantages are so impor-
tant that array CGH will soon become the first
choice of investigation in patients with men-
tal retardation and/or multiple congenital ab-
normalities. Conventional karyotyping will take
second position in all cases. In positive cases,
karyotyping can shed light on the nature of the
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chromosomal aberration (array CGH only pro-
duces information on which regions are gained
or lossed, but does not provide any information
on the underlying rearrangement). For negative
cases, karyotyping will be performed to exclude
balanced rearrangements.
Recent developments in whole genome ampli-
fication protocols are opening the way for new
applications for array CGH, i.e. single-cell ana-
lysis [204, 205]. These single-cell techniques
can be employed in certain tumor samples, but
also offer new possibilities for the reliable single-
cell analysis in preimplantation genetic diagno-
sis (PGD) [206]. Several laboratories have used
FISH to screen for the most common aneuploi-
dies leading to failed implantation or abortion
(trisomy 13, 16, 18, 21, 22, X and Y) after
in vitro fertilization in older patients. However,
aneuploidy of other chromosomes (although not
viable) is not excluded. Moreover FISH screen-
ing is very labor intensive and often hard to in-
terpret. With array CGH it becomes feasible
to screen the whole genome of a single blasto-
cyst for aneuploidy, and even structural aberra-
tions [204, 205]. Despite all these advantages,
classical karyotyping can be expected to remain
with us for some time as this is currently the only
method which allows the unequivocal screening
for balanced chromosomal rearrangements (e.g.
in case of sub- or infertility or de novo translo-
cations in children with mental retardation). In
time, other approaches, perhaps entire genome
sequencing, may also make this aspect of karyo-
typing obsolete.
Future Opportunities for the Search for Ge-
netic Causes for Idiopathic Mental Retardation
Although the detection rate of these new
high resolution DNA copy number analysis
techniques is high (˜11%), the underlying
(genetic) cause for MR/MCA in many patients
remains unknown. Mental retardation is often
a specific and probably many hundreds or
even thousands of genes may lead to mental
retardation if inactivated. Single nucleotide
changes in a gene can be causal but beyond
doubt in many cases the underlying mechanism
in these patients will be the result of subtle
interplay between different genes. Furthermore,
the role of epigenetic modifications remains to
be investigated. Large association studies might
be helpful in the identification of multifactorial
or multigenic causes, but as it is assumed
that many genes might be involved in mental
retardation, also these studies will have many
difficulties detecting the causal genes. One
alternative possibility to study genetic causes
for mental retardation could be through gene
expression profiling of brain tissue, but for
obvious reasons such studies are precluded in
patients. Although mouse models could offer a
realistic alternative for such studies, assessing
the phenotypes of mental retardation in mice
represents another daunting challenge.
Initial arrays were constructed with a 1 Mb
resolution, already improving the resolution of
conventional karyotyping 5 to 10 times [83, 84].
Although very labor intensive, tiling path large
insert clone arrays were constructed with reso-
lutions up to ˜75 kb [63, 64]. Nowadays, BAC
and PAC microarrays are replaced by oligonu-
cleotide arrays enabling very high resolutions
(up to 6 kb) both in research and diagnos-
tics [207]. Genomic copy number scanning of
all 250 000 exons in the human genome will
enable immediate disease gene identification in
cases exhibiting single exon duplications and/or
deletions, further improving the diagnostic yield
of array CGH [208]. For some custom applica-
tions, tiling path arrays have been developed,
enabling the resequencing of parts of the/a
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genome [66]. How much further these technical
improvements will go, is hard to predict, but
many outstanding scientists predict, that it
will become feasible to (re)sequence everyone’s
genome within a couple of years. Although the
scientific information this will provide is beyond
imagination, it will also put us for some very
difficult (ethical) issues and choices.
In conclusion, this thesis illustrates several
important applications of array CGH in the field
of clinical cytogenetics.
Important consequences of this new performant
methodology are improved genetic diagnosis in
patients with unexplained mental retardation,
progress towards genotype-phenotype correla-
tion in such patients and identification of candi-
date disease genes. Functional studies of these
genes will contribute to our understanding in
their involvement in morphogenesis and embryo-
genesis of the brain and other organs.
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Summary
About one to three percent of the human population is aﬄicted by mild to severe mental
retardation, often in association with congenital abnormalities (MR/CA). These abnormalities
in normal human morphogenesis may express themselves as subtle dysmorphic signs not causing
any harm or present as severe disabling and life-threatening malformations such as congenital
heart defects. It is well established that constitutional chromosomal aberrations are an important
cause for MR/CA. The screening for such chromosomal rearrangements is done by widely used
routine analysis of banded metaphase chromosomes (karyotyping). Given the limited resolution
of such analyses (5-10 Mb), it was anticipated that a significant number of submicroscopic
deletions or duplications (DNA copy number variations, CNV) were overlooked in patients with
idiopathic mental retardation with or without congenital anomalies. This thesis represents one
of the first exhaustive studies of this patient group using a new and more sensitive method
for detection of CNVs. This technique, termed array comparative genomic hybridization (array
CGH), allows the genome wide screening for submicroscopic aberrations in one single experiment.
Array CGH uses reporter DNA molecules more or less evenly spread throughout the entire
genome which are spotted or synthesized in an array on a glass slide. Each reporter is used
to interrogate the DNA copy number of a specific genomic region through the competitive
hybridization of differentially fluorescent labeled patient and control DNA. Together with the
tedious optimalization of the technique, also a web based open source (MySQL) database
platform was developed for the analysis and visualization of large amount of array CGH data
(medgen.ugent.be/arrayCGHbase) (paper 6). A total of 140 carefully clinically selected patients
with mental retardation and/or congenital abnormalities were analyzed for hidden chromosomal
aberrations in a collaborative effort with the Center for Medical Genetics Leuven (KUL). This
initial study together with a review of other published investigations, allowed for the first time
to establish a reliable figure of the number of submicroscopic CNVs in this patient population.
When excluding patients with subtelomeric imbalances which could be identified through FISH or
MLPA analyses, array CGH still allowed to detect CNVs in an additional ˜8% of patients (paper
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2). A major challenge resulting from this new flow of information is the search and description
of new microdeletion/microduplication syndromes. Although most CNVs seemed to be scattered
across the entire genome we were able to describe a new microdeletion syndrome characterized
by osteopoikilosis, mental retardation and short stature. This observation was facilitated through
the identification of LEMD3 as the causal gene for osteopoikilosis, Buschke-Ollendorff syndrome
(BOS) and melorheostosis in the 12q14.3 deleted interval and subsequent, the finding of two
additional patients with a 12q14.3 microdeletion (paper 3). The present work also illustrates
the possible contribution of array CGH in the delineation of the critical region for recurrent
deletion syndromes. In this study we identified a small interstitial deletion on chromosome
18q12.3 in a patient with clinical features of the del(18)(q12.1q21.1) syndrome. We were able
to delineate the critical region for this syndrome to an interval of 1.8 Mb, enabling hereby the
determination of the crucial genes for this microdeletion syndrome (paper 4). This thesis also
further illustrates the power of combined flow cytometry and array CGH for rapid identification
of translocation breakpoints. Using this approach we were able to identify OPHN1 as the causal
gene for the observed mental retardation and overgrowth in a girl with an apparent balanced
t(X;9) translocation (paper 5).
In conclusion, the presented work clearly illustrates several important applications of array
CGH in the field of clinical cytogenetics. The use of this new performant methodology will
greatly improve the diagnostic yield in patients with unexplained mental retardation, provide
more insights into genotype-phenotype correlations and ultimately lead to the identification of
the causal genes. Functional studies of these gene products will enhance our understanding of
the genetic regulation in normal human morphogenesis, embryogenesis and brain functioning.
Finally, it is my believe that implementation of array CGH will represent a major and perhaps
last wave of innovation in cytogenetics, as the latter may become largely redundant. Ultimately
and perhaps earlier than we can anticipate, sequencing of the whole genome of a patient may
eventually emerge as the method of choice.
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Samenvatting
Ongeveer twee tot drie percent van de bevolking is getroffen door milde tot ernstige mentale
retardatie, vaak in associatie met congenitale afwijkingen (MR/CA). Deze afwijkingen in de
normale humane morfogenese kunnen zich presenteren als milde dysmorfe kenmerken zonder ern-
stige defecten, of als ernstige levensbedreigende malformaties zoals congenitale hartafwijkingen.
Het is algemeen gekend dat constitutionele chromosomale afwijkingen een belangrijke oorzaak
vormen van MR/CA. Het onderzoek van dergelijke patie¨nten voor chromosomale afwijkingen
gebeurt door de wijdverspreide routine analyse van gebandeerde metafase chromosomen. Door
de lage resolutie van dergelijk onderzoek (5-10 Mb), werd verwacht dat een belangrijke proportie
van alle submicroscopische deleties en duplicaties (DNA kopie aantal veranderingen) werden
gemist in patie¨nten met mentale retardatie met of zonder congenitale afwijkingen. Deze
thesis is e´e´n van de eerste studies op deze patie¨ntengroep, waarbij gebruik werd gemaakt van
een nieuwe en meer sensitieve methode voor de detectie van submicroscopische afwijkingen.
Microarray-gebaseerde vergelijkende genoom hybridisatie (array CGH), laat de genoomwijde
detectie toe van submicroscopische afwijkingen in e´e´n enkele experiment. Array CGH maakt
gebruik van DNA molecules die min of meer gelijkmatig over het genoom verspreid zijn en
ge¨ımmobiliseerd of gesynthetiseerd worden op een microscoop draagglaasje. Elke DNA molecule
(reporter) wordt gebruikt om de DNA status te onderzoeken van een specifieke genomische regio
door de competitieve hybridisatie van het differentie¨el fluorescent gemerkte patie¨nt en controle
DNA. Samen met de nauwgezette optimalisatie van de techniek, werd een web gebaseerd ‘open
source‘ (MySQL) platform ontwikkeld voor de analyse en visualisatie van array CGH data.
(medgen.ugent.be/arrayCGHbase) (paper 6). Een totaal van 140 klinisch geselecteerde patie¨nten
met mentale retardatie en/of congenitale afwijkingen werden onderzocht voor submicroscopische
chromosomale afwijkingen in een gezamenlijke studie met het Centrum voor Menselijke Erfeli-
jkheid Leuven (KUL). Deze initie¨le studie, samen met een overzicht van de reeds gepubliceerde
onderzoeken, maakte het voor de eerste maal mogelijk een betrouwbare incidentie van deze
submicroscopische chromosomale afwijkingen in de patie¨ntenpopulatie te schatten. Wanneer
subtelomerische deleties, die eveneens met FISH of MLPA kunnen worden opgespoord, buiten
beschouwing werden gelaten, werd er in ˜ 8% van de patie¨nten een submiscroscopische afwijking
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gedetecteerd (paper 2). Een enorme uitdaging voortvloeiend uit deze initie¨le studie was de
zoektocht naar, en de beschrijving van, nieuwe microdeletie/microduplicatie syndromen. Hoewel
de meeste kopie-aantal veranderingen verspreid over het genoom lagen, waren we toch in staat
een nieuwe recurrente microdeletie, gekarakteriseerd door osteopoikilose, mentale retardatie en
kleine gestalte te beschrijven. Een eerste patie¨nt met een microdeletie van chromosoomband
12q14.3 maakte het mogelijk LEMD3 als causaal gen voor osteopoikilose, Buschke-Ollendorff
syndroom (BOS) en melorheostosis te identificeren. Vervolgens werd in twee andere patie¨nten
met osteopoikilose, mentale retardatie en kleine gestalte eveneens een deletie van deze regio
gedetecteerd (paper 3). Dit werk illustreert eveneens de bijdrage van array CGH in de afbakening
van de kritische regio van recurrente microdeletie syndromen. In deze studie identificeerden we
een kleine interstitie¨le deletie op chromosoom 18q12.3 in een patie¨nt met de klinische kenmerken
van het del(18)(q12.1q21.1) syndroom. We waren in staat de kritische regio voor dit syndroom
af te bakenen tot een 1,8 Mb regio, waarbij we eveneens de mogelijks causale genen konden
identificeren (paper 4). Deze thesis illustreert eveneens de kracht van het combineren van flow
cytometrie en array CGH voor de snelle identificatie van translocatie breukpunten. Met deze
nieuwe aanpak, was het mogelijk om OPHN1 als causaal gen te identificeren in een patie¨nte
met mentale retardatie en overgroei en een schijnbaar gebalanceerde t(X;9) translocatie (paper 5).
Als conclusie, kunnen we stellen dat deze thesis verschillende belangrijke applicaties van
array CGH in de klinische (cyto)genetica illustreert. Het gebruik van deze performante
methodologie zal leiden tot een hogere detectieratio van de ethiopathogenese in patie¨nten met
idiopathische mentale retardatie. Bovendien zal deze technologie verdere inzichten verschaffen in
genotype-fenotype correlaties en uiteindelijk leiden tot de identificatie van genen verantwoordelijk
voor mentale retardatie en aangeboren afwijkingen. Functioneel onderzoek van deze genen zal
ons inzichten verschaffen in de normale humane ontwikkeling, embryogenese en werking van onze
hersenen. Ten slotte, ben ik ervan overtuigd, dat array CGH de volgende en misschien wel laatste
golf van innovatie is in de cytogenetica. Uiteindelijk, en misschien sneller dan we verwachten,
zal sequenering van het volledige genoom van de patie¨nt de techniek bij uitstek worden in de
genetische diagnostiek.
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Re´sume´
Les aberrations chromosomiques constitutionnelles constituent une cause importante de retard
mental et d’anomalies conge´nitales. Ces anomalies peuvent varier de signes dysmorphiques
discrets a` de multiples malformations conge´nitales comme des malformations cardiaques, des
malformations des membres, etc. L’analyse des bandes chromosomiques est la technique la
plus utilise´e en cytoge´ne´tique classique mais a une re´solution limite´e (5 a` 10 Mb). L’e´tude des
chromosomes et les analyses ge´ne´tiques en ge´ne´ral ont largement contribue´ a` l’identification
des causes de retard mental et/ou de malformations conge´nitales. La mise en e´vidence d’une
cause ge´ne´tique est d’une importance cruciale dans la prise en charge de ces patients et pour
le conseil ge´ne´tique familial. En raison d’une re´solution limite´e du caryotype conventionnel,
l’e´thiopathogene`se des anomalies conge´nitales et du retard mental reste cependant inconnue
dans un tiers des patients. L’advenue d’une nouvelle technique d’hybridation comparative du
ge´nome a` haute re´solution sur puce a` ADN (CGH array) permet une analyse globale du ge´nome
re´ve´lant pre´cise´ment des aberrations chromosomiques infra-microscopiques chez ces patients
atteints d’un retard mental ou de malformations conge´nitales. Son principe consiste a` cohybrider
une meˆme quantite´ d’ADN d’un malade et d’un te´moin, marque´ chacun par un fluorochrome
diffe´rent, sur des sondes d’ADN fixe´es sur une lame de verre. Apre`s l’hybridation, la fluorescence
est mesure´e et le rapport de l’intensite´ de fluorescence de l’ADN du malade sur celle de l’ADN
normal (= ratio) est calcule´ pour chaque clone. Ce ratio est directement corre´le´ au nombre
de copies d’ADN du segment e´tudie´. Une puce a` chromosome artificiel bacte´rien (BAC-array)
pange´nomique d’une re´solution moyenne de 1 Mb a pu eˆtre produite en collaboration e´troite
avec le centre de Ge´ne´tique Humaine de Leuven, Belgique et le Wellcome Trust Sanger Institute,
Hinxton, Cambridge, UK. Plusieurs parame`tres ont e´te´ optimalise´s et des crite`res de qualite´
pour les re´sultats de CGH array ont e´te´ e´tablis. Une e´tape importante dans la proce´dure de
CGH array est l’analyse finale des donne´es et la visualisation des re´sultats. Une base de donne´es
publique et figurant sur le re´seau fut de´veloppe´e, permettant ainsi la sauvegarde, l’analyse et la
visualisation d’un grand nombre de donne´es typiquement ge´ne´re´es lors d’analyses en CGH array
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(medgen.ugent.be/arrayCGHbase) (paper 6). Suite a` la re´ussite de la mise en uvre de la CGH
array, une large cohorte d’environs 140 patients pre´sentant un retard mental et/ou des anomalies
conge´nitales fut analyse´e a` la recherche d’aberrations infra-microscopiques. Une aberration
chromosomique fut de´tecte´e dans ˜ 8% des cas elle fut pre´sume´e eˆtre la cause du phe´notype
observe´ (paper 2). Dans une seconde partie de cette e´tude, l’utilisation de la CGH array a` haute
re´solution pour l’analyse de la de´le´tion 12q14.3 a contribue´ a` l’identification du ge`ne LEMD3, ge`ne
causal de l’oste´opoikilose, du syndrome de Buschke-Ollendorff (BOS) et de la me´lorhe´ostose. De
plus, plusieurs autres patients pre´sentant une de´le´tion au niveau de cette bande chromosomique
ont e´te´ identifie´s. Ces donne´es sont suggestives d’un nouveau syndrome microde´le´tionnel
re´current sur la bande chromosomique 12q14.3 caracte´rise´ par une oste´opoikilose, un retard
mental ainsi qu’une petite taille (paper 3). En outre, la de´couverte par CGH array d’une
petite de´le´tion interstitielle sur le chromosome 18q12.3 nous a permis de de´limiter une re´gion
critique pour le syndrome de del(18)(q12.1q21.1). Ce fut un des premiers syndromes de´le´tionnels
re´currents pour lesquels la CGH array a pu contribuer a` la de´limitation d’une re´gion critique.
De tels re´sultats constituent une ouverture vers l’identification de ge`nes causaux (paper 4). Ce
travail de´montre e´galement l’utilite´ de la CGH array et plus en particulier de l’array painting
pour l’e´tude de translocations chromosomiques balance´es apparentes. Cette approche a permis
l’identification de OPHN1 comme ge`ne causal du phe´notype associant un retard mental, un
surpoids et une croissance acce´le´re´e chez un patient pre´sentant une translocation t(X;9) (paper 5).
En conclusion, cette the`se illustre de nombreuses applications importantes de la CGH ar-
ray en cytoge´ne´tique clinique. Cette nouvelle me´thodologie permet une ame´lioration du
diagnostic ge´ne´tique pour des patients atteints d’un retard mental inexplique´, un progre`s dans
la corre´lation ge´notype-phe´notype ainsi que l’identification de ge`nes candidats de la maladie.
L’e´tude fonctionnelle de ces ge`nes contribuera a` une meilleure compre´hension de l’implication
de ces ge`nes dans la morphogene`se et dans l’embryogene`se du cerveau et d’autres organes.
Finalement, j’ai l’intime conviction que la CGH array sera une e´tape majeure et peut-eˆtre la
dernie`re e´tape innovatrice en cytoge´ne´tique, avant que celle-ci ne disparaisse de´finitivement. On
peut penser qu’a` court terme le se´quenc¸age du ge´nome du patient devienne la me´thode de choix.
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Abbreviations
AAIDD American Association on Intellectual and Developmental Disabilities (formerly AAMR)
AAMR American Association on Mental Retardation
ADHD attention-deficit hyperactivity disorder (ADHD)
APP amyloid beta (A4) precursor protein
BAC bacterial artificial chromosome
CATCH 22 cardiac defects, abnormal facies, thymic hypoplasia/aplasia, cleft palate, hypocal-
cemia, and 22q11 deletion
cDNA copy deoxyribonucleic acid
CGH comparative genomic hybridization
CHARGE Coloboma of the eye, central nervous system anomalies, Heart defects, Atresia of the
choanae, Retardation of growth and development, Genital and/or urinary defects, Ear anomalies
and/or deafness
COBRA combined binary ratio labelling
CREBBP CREB-Binding Protein
CT computed tomography
CYLN2 cytoplasmic linker 2
DNA deoxyribonucleic acid
DOP-PCR degenerate oligonucleotide primer polymerase chain reaction
DSM-IV diagnostic and statistical manual of mental disorders, 4th edition
EEG electroencephalogram
ELN elastin
EST expressed sequence tag
ETS2 Erythroblastosis Virus E26 Oncogene Homolog 2
EXT1 exostoses (multiple) 1
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FISH fluorescence in situ hybridisation
FMR1 fragile X mental retardation 1
GATA4 GATA binding protein 4
GTF2I general transcription factor II, i
GTF2IRD1 GTF2I repeat domain containing 1
HGD homogentisate 1,2-dioxygenase
HMGA2 high mobility group AT-hook 2
HNPP hereditary neuropathy with liability to pressure palsies
ICD-10 international classification of diseases 10th edition
IQ intelligence quotient
JAG1 jagged 1
Kb kilobase (1000 basepairs)
LCR low copy repeats
LIMK1 LIM domain kinase 1
LINE long interspersed element
LIS1 lissencephaly 1
LOH loss of heterozygosity
MAPH multiplex amplifiable probe hybridization
MAPT microtubule-associated protein tau
Mb megabase (1000000 basepairs)
MECP2 methyl-CpG-binding protein-2
M-FISH multiplex FISH or multicolour FISH
MLPA multiplex ligation-dependant probe amplification
MR mental retardation
MR/MCA mental retardation/multiple congenital abnormalities
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
MSX1 MSH Homeobox 1
NAHR non allelic homologous recombination
NDN necdin homolog (mouse)
NF1 neurofibromin 1
NHEJ nonhomologous end-joining
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NIH National Institutes of Health
NMR nuclear magnetic resonance
OPHN1 oligophrenin 1
PAC P1-plasmid derived artificial chromosome
PAGE polyacrylamide gel electrophoresis
PAX6 paired box gene 6 (aniridia, keratitis
PCR polymerase chain reaction
Perl Practical Extraction and Report Language
PHP php hypertext prepocessor
PKU phenylketonuria
RAI1 retinoic acid-induced 1
RNA ribonucleic acid
RPCI-11 Roswell Park Center Institute-11 BAC library
SINE short interspesed element
SKY spectral karyotyping
SMS Smith-Magenis syndrome
SNP single nucleotide polymorphism
SNRPN small nuclear ribonucleoprotein polypetide N
SRO shortest region of overlap
TBX1 T-box transcription factor
TRPS1 trichorhinophalangeal syndrome 1
UBE3A ubiquitin protein ligase E3A
VCFS velocardiofacial syndrome
VDJ variable, diversity and joining gene segments
VEGF vascular endothelial growth factor
VNTR variable number of tandem repeats
WAIS Wechsler adult intelligence scale
WHSC1 Wolf-Hirschhorn syndrome candidate 1
WT1 Wilms tumor 1
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